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Obesity has been reported as an independent risk factor for chronic kidney disease, leading to 3 
glomerulosclerosis and renal insufficiency. To assess the relationship between a reduced nephron 4 
number and a particular susceptibility to obesity-induced renal damage, mice underwent uninephrectomy 5 
(UNX) followed by either normal chow or high-fat diet (HFD) and were compared with sham-operated 6 
control mice. After 20 weeks of dietary intervention, HFD-fed control mice presented characteristic 7 
features of progressive nephropathy, including albuminuria, glomerulosclerosis, renal fibrosis and 8 
oxidative stress. These changes were more pronounced in HFD-fed mice that had undergone 9 
uninephrectomy. Analysis of gene expression in mouse kidney by whole genome microarrays indicated 10 
that high fat diet led to more changes in gene expression than uninephrectomy. HFD affected mainly 11 
genes involved in lipid metabolism and transport, whereas the combination of UNX and HFD additionally 12 
altered the expression of genes belonging to cytoskeleton remodeling, fibrosis and hypoxia pathways.  13 
Canonical pathway analyses identified the farnesoid X receptor (FXR) as a potential key mediator for the 14 
observed changes in gene expression associated with UNX-HFD. In conclusion, HFD-induced kidney 15 
damage is more pronounced following uninephrectomy and is associated with changes in gene 16 
expression that implicate FXR as a central regulatory pathway. 17 
 18 
 19 




Abbreviations:  UNX: uninephrectomy; HFD: high fat diet; FXR: farnesoid X receptor; CKD: chronic 24 
kidney disease; OATP, organic anion transporting polypeptide; OAT, organic anion transporter; SLC/Slc, 25 
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1. Introduction 1 
 2 
Obesity is not only associated with an increase in morbidity, mortality and reduction in life expectancy, but 3 
also leads to an increase in the incidence of diabetes, hypertension and dyslipidemia [1, 2]. Furthermore, 4 
obesity is now being increasingly recognized as a major and independent risk factor for the development 5 
of chronic kidney disease (CKD) [3, 4], focal glomerulosclerosis [5], and end stage renal disease (ESRD) 6 
[6-9]. Recent observational studies demonstrate that obesity is an independent risk factor for CKD in 7 
patients with reduced renal mass [6, 9]. Currently, a growing population lives with reduced renal mass 8 
considering the higher rates of primary kidney tumor in adults and congenital solitary kidney in children, 9 
as well as the rising number of living kidney donors [10-13]. Given the epidemics of overweight in the U.S. 10 
and worldwide [14, 15], the number of obese people with reduced renal mass is expected to increase.  11 
Despite the public health and clinical implications of the relationships between obesity and kidney injury in 12 
patients that have undergone nephrectomy [6, 9], the mechanisms leading to obesity-induced renal 13 
damage in reduced renal mass are less clear. 14 
  15 
To date, clinical and experimental studies have shown that the characteristic features of obesity induced 16 
kidney injury [16, 17] contribute to albuminuria, a progressive decline in renal function and ultimately 17 
glomerulosclerosis and tubulointerstitial fibrosis [18-22]. Since chronic kidney disease is a complex kidney 18 
disease, interruption of a single pathway is unlikely to result in a significant therapeutic benefit. Further 19 
understanding of the pathogenesis of renal failure thus requires global expression analysis of disease 20 
states using genomics and/or proteomics tools [23-27]. 21 
  22 
In this study, high-fat-diet-fed mice were used as an obesity model. We examined kidney function and 23 
histological changes of 20-week uninephrectomized (UNX) mice fed a chow diet (UNX-chow), UNX mice 24 
fed a high fat diet (UNX-HFD) and sham-operated control mice (Sham-chow and Sham-HFD). Gene 25 
expression in kidney tissue of these four groups was also analyzed to better comprehend the molecular 26 
mechanisms underlying advanced renal disease and the pathogenetic role of obesity in the onset of 27 
proteinuria and renal insufficiency.  UNX-HFD mice presented higher degrees of progressive nephropathy, 28 
albuminuria and renal fibrosis. Moreover, we observed marked changes in a number of genes and gene 29 
families involved in cytoskeleton remodeling, fibrosis and lipid metabolism in the UNX-HFD group and 30 
novel pathways linked with farnesoid X receptor (FXR) signaling that have not been previously associated 31 
with renal disease progression. The altered expression of some of these genes is also associated with 32 
possible protective and compensatory mechanisms.  Additionally, our results indicate that obesity-induced 33 
chronic renal disease is accelerated in UNX. 34 
 35 
  36 
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2. Materials and Methods 1 
 2 
2.1 Uninephrectomy 3 
Male C57/BJ mice aged 6 weeks were randomly assigned to uninephrectomy (UNX) or sham procedures 4 
and fed with a high fat diet (D12331; ResearchDiets, NJ, USA) or control chow diet (Provimi Kliba). Mice 5 
were divided into 4 groups of 6: Sham-chow, UNX-chow, Sham-HFD and UNX-HFD.  For uninephrectomy, 6 
mice were initially anesthetized with 3% to 5% isoflurane, orally intubated, and mechanically ventilated. 7 
Anesthesia was maintained with 1.5% to 2% isoflurane delivered in oxygen. The left kidney was surgically 8 
removed via a left paramedian incision on the back.  The adrenal gland was carefully freed from the upper 9 
pole of the renal capsule before the renal pedicle was ligated and the kidney removed.  For sham surgery, 10 
the kidney was manipulated without ablation.  All mice were sacrificed under anesthesia 20 weeks after 11 
surgery and kidneys were harvested.  Half of the kidney from each animal was snap frozen in liquid 12 
nitrogen and stored at -80°C for RNA and protein extraction.  The other half was fixed with formalin for 13 
histology. All protocols conformed to the Swiss animal protection laws and were approved by the Cantonal 14 
Veterinary Office in Zurich, Switzerland. 15 
 16 
2.2 Measurement of plasma and urine samples 17 
For 24-hour urine collection, individual mice were placed in metabolic cages with access to diets.  Urinary 18 
albumin and creatinine concentrations were measured with the Albumin mouse ELISA kit (ab108792, 19 
Abcam, Cambridge, UK) and Creatinine assay kit (ab65340, Abcam, Cambridge, UK).  Urinary H2O2 20 
levels were measured using the Amplex Red H2O2 assay kit (A12214, Invitrogen, CA, US).  Plasma 21 
samples were obtained from tail blood of fasted mice.  Plasma cholesterol and triglyceride levels were 22 
measured by the Amplex Red cholesterol assay kit (A12216, Invitrogen, CA, US) and theTriglyceride 23 
assay kit (ETGA-200, EnzyChrom, Aachen, Germany), respectively. 24 
 25 
2.3 Assessment of renal pathology and immunostaining 26 
Kidneys were fixed overnight in 10% neutral buffer formalin and embedded in paraffin.  Tissue sections 27 
were cut at 3 μm and stained for hematoxylin and eosin, periodic acid-Schiff (PAS) and Masson’s 28 
trichrome using standard protocols. Mesangial area was determined from PAS stained sections and 29 
fibrotic area was assessed from trichrome stained sections as described [28, 29].  Briefly, digital images 30 
of random high power fields were analyzed by a blind observer.  The cross-sectional area of the 31 
glomerulus or area of fibrosis was determined by using the program Adobe Photoshop.  4 mice were 32 
analyzed per group. Immunostaining was performed on paraffin sections using a microwave based 33 
antigen retrieval technique. The antibodies used in this study included Actn1 (Novus biologicals, 34 
Cambridge, UK), Slc27a4 (Proteintech, Manchester, UK), TNFα (Abcam, Cambridge, UK) and Cyp4a 35 
(Santa Cruz, CA, US). The antibody against Slco1a1 was previously raised in our group (Dr. Bruno 36 
Stieger). Sections were treated with the Envision
+
 DAB kit (Dako, Denmark) according to the 37 
manufacturer’s instruction. 38 
 39 
2.4 Microarray and gene expression analysis 40 
RNA was extracted from frozen kidney using RNeasy Microarray Tissue mini kit (73304, Qiagen, 41 
Germany), followed by on column DNase digestion to remove any contaminating genomic DNA.  RNA 42 
samples from 4 mice per group were subjected to microarray analysis.  Briefly, 100 ng of total RNA was 43 
reverse-transcribed into double-stranded cDNA, which was linearly amplified and labelled with Cy3 dye. 44 
Following quantification using a Nanodrop spectrophotometer (Witec, Luzern, Switzerland) and quality 45 
assessment  with Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA), 1.6 μg of the 46 
obtained Cy3-labeled cRNA was hybridized to Mouse GE 4x44K v2 Microarrays (Agilent Technologies, 47 
Santa Clara, CA) according to the manufacturer’s protocol. Arrays were scanned with an Agilent 48 
G2565CA Microarray Scanner System (Agilent, Santa Clara, CA).  Raw intensity data were obtained 49 
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using Agilent's Feature Extraction Software version 10.7 for array image analysis and the calculation of 1 
spot intensity measurements. Data analysis was carried out with R/Bioconductor. The processed 2 
intensities and normalized across samples were loaded by using quantile normalization. All microarray 3 
data was submitted to the Gene Expression Omnibus (accession number GSE53996). Differential 4 
expression was computed using the limma package. More details on analysis methods can be found at 5 
http://fgcz-bfabric.uzh.ch/wiki/tiki-index.php?page=app.two_groups. Gene oncology analysis, network 6 
analysis and canonical pathway analysis of the microarray data were completed using the Ingenuity 7 
Pathway Analysis (Qiagen, Redwood, CA) software, MetaCore online service (Thomson Reuters), and 8 
Subio platform (Subio Inc, Kagoshima, Japan). 9 
 10 
2.5 Semi-quantitative RT-PCR 11 
Validation of microarray data was performed for selected differentially expressed genes by sqRT-PCR.  12 
Briefly, 2 μg total RNA (n = 3 to 4), from the same samples sent for microarray, was reverse transcribed 13 
using oligo-dT priming and SuperscriptII (Invitrogen, CA, US). First-strand complementary DNA was used 14 
as the template for real-time polymerase chain reaction analysis with TaqMan master mix and primers 15 
(Applied Biosystems, CA, US). Transcript levels, determined in two independent complementary DNA 16 
preparations, were calculated as described and expressed relative to villin as housekeeping gene. 17 
 18 
2.6 Statistical analyses 19 
Data are expressed as mean ± SEM. For microarray data, comparison was assessed by student’s t test 20 
with R/Bioconductor to generate differentially expressed genes (UNX-Chow vs. Sham-Chow; UNX-HFD 21 
vs. Sham-HFD; Sham-HFD vs. Sham-Chow; UNX-HFD vs. UNX-Chow). For other data regarding to 22 
baseline characteristic analysis and histological analysis, comparison between groups was assessed by 23 
one-way ANOVA followed by Bonferroni’s test.  Statistical analyses were performed with GraphPad 24 
software. 25 
 26 
2.7 Supplementary material 27 
The following supplementary information is available online: 28 
Table S1.  Differentially expressed genes (≥ 1.7 fold) in 20-week sham-HFD kidneys as compared with 29 
sham-chow kidneys 30 
Table S2. Differentially expressed genes (≥ 1.7 fold) in 20-week remnant UNX-HFD kidneys as compared 31 
with UNX-chow kidneys 32 
Table S3. Genes differentially expressed in both UNX and sham-operated mice fed a high fat diet (≥ 1.7 33 
fold, p<0.05) 34 
Table S4. Genes that show a change in expression level only in UNX-HFD remnant kidneys (≥ 1.7 fold, 35 
p<0.05) 36 
Table S5. Formula of high fat diet #D12331 37 
Figure S1.  Thin layer chromatography (TLC) results of kidney lipid composition. (A, B) Representative 38 
images taken from TLC results. Quantitative analyses of total phospholipids (C) and cholesterol (D) from 39 
each group (n = 4 / group, data represent mean ± SEM). 40 
Supplementary method.  Thin layer chromatography 41 
  42 
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3. Results 1 
 2 
3.1 Systemic metabolic abnormalities 3 
To evaluate the effect of uninephrectomy (UNX) on HFD-induced renal disease, mice at six weeks of age 4 
underwent UNX, followed by either a normal or high fat diet (HFD) for 20 weeks. The characteristics of 5 
the four groups at 20 weeks of the experimental period are presented in Table 1. Both sham and UNX 6 
mice that consumed HFD showed markedly increased body weight. The body weight of UNX-chow and 7 
UNX-HFD mice tended to be lower than in their counterparts that had undergone sham operation, 8 
although this difference did not reach statistical significance during the observation period. UNX 9 
significantly increased the weight of the remnant kidney, especially in mice fed the HFD. Mice from the 10 
HFD group showed significantly higher plasma triglyceride and cholesterol levels. UNX, however, had no 11 
effects on these biochemical parameters. As shown in Fig. 1, the biochemical analysis of creatinine and 12 
albumin confirmed chronic renal disease progression in UNX-HFD mice. Sham-operated mice consuming 13 
the HFD developed progressive albuminuria and UNX produced a more striking increase in the 14 
albumin/creatinine ratio in mice fed the HFD at 20 weeks. Moreover, the urinary H2O2 level was also 15 
significantly higher in the UNX group after 20 weeks of the high fat diet, indicating a greater degree of 16 
oxidative stress in the UNX-HFD remnant kidney. 17 
 18 
3.2 UNX accelerates renal fibrosis and glomerulosclerosis in obese mice 19 
The effect of UNX on the acceleration of fibrosis and glomerulosclerosis in obese mice was evident by 20 
trichrome and PAS staining. As shown in Fig. 2, HFD increased fibrosis in sham-operated mice assessed 21 
after 20 weeks of feeding (Fig. 2 G). However, kidney sections from UNX-HFD mice showed the most 22 
severe degree of fibrosis (Fig. 2 H). By quantitative analysis (Fig. 2 M), interstitial fibrosis, as determined 23 
by Trichrome staining, was approximately 2-fold greater in UNX-HFD kidneys than in Sham-HFD kidneys.  24 
Furthermore, quantitation from PAS-stained sections showed that the mesangial matrix content was 25 
increased significantly by UNX in HFD kidneys compared with the sham-operated counterparts (Fig. 2 I-L 26 
and N). 27 
 28 
3.3 Effects of UNX and HFD on gene expression in the kidney 29 
In parallel, global gene expression in the 20-week remnant kidneys of uninephrectomized mice fed either 30 
a chow or a high fat diet was compared with kidney tissue from the corresponding sham groups.  3-4 total 31 
RNA samples per group were analyzed and gene expression was compared between groups. 32 
 33 
First, gene expression was compared between UNX-chow mice versus sham-chow mice (UNX-34 
chow/Sham-chow) and between UNX-HFD mice versus sham-HFD mice (UNX-HFD/Sham-HFD).  By 35 
using a ≥ 1.7-fold change as a cut-off, only 157 genes were differentially expressed between the UNX-36 
chow/Sham-chow groups and 136 genes between the UNX-HFD/Sham-HFD groups (Fig. 3 A).  Analysis 37 
of plot sources of variation confirmed that the impact of the high fat diet was greater than that of UNX on 38 
gene expression in these four groups (Fig. 3 B). 39 
 40 
Next, in order to identify genes altered by HFD, the following datasets were compared: UNX-HFD versus 41 
UNX-chow (designated as UNX dataset) and sham-HFD versus sham-chow (designated as sham 42 
dataset).  Comparison of data from Sham-HFD versus Sham-chow and data from UNX-HFD versus UNX-43 
chow revealed that 2441 and 2581 genes, respectively, were significantly increased or decreased at least 44 
1.7-fold (Fig. 3 A, Tables S1 and S2).  Interestingly, a substantial number of genes (1289 genes) 45 
overlapped in being differentially expressed in both the UNX-HFD/UNX-chow and the sham-HFD/sham-46 
chow datasets, as shown by Venn diagram analysis (Fig. 4 A and Table S3).  The overlapping genes in 47 
both the UNX and sham datasets included genes involved in lipid transport and metabolism (Fig. 4 B). 48 
However, genes implicated in ion transport and in renal hypoxia showed altered expression only in the 49 
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UNX-HFD remnant kidneys (Fig. 4 C, Table 3 and Table S4).  Importantly, the altered expression of genes 1 
responsive to hypoxia (Table 3) is consistent with the increased urinary H2O2 levels in UNX-HFD mice. 2 
 3 
The differences between the two datasets were further confirmed by network and canonical pathway 4 
analyses.  Network analyses with these two datasets are shown in Fig. 5. The common networks from 5 
both datasets were associated with cell adhesion, inflammation and apoptosis, whereas networks linked 6 
to cytoskeleton remodeling and cell-matrix adhesion mainly fell into the UNX dataset. Table 2 shows the 7 
discrepancies between the canonical pathways in each dataset. The FXR pathway is the top canonical 8 
pathway in the UNX-HFD dataset with 14 genes altered 1.7-fold, whereas only 10 genes are significantly 9 
changed in the Sham-HFD dataset (Table 3). Several canonical pathways which relate to fibrogenesis 10 
were also shown to be significantly changed in the UNX dataset, including decreased expression of 11 
genes within the BMP pathway and increased expression of genes within the Wnt signaling pathway 12 
(Table 3), which is in line with the histological observations (Fig. 2 H and M). 13 
 14 
3.4 Validation of microarray findings with semi-quantitative RT-PCR and immunostaining 15 
To validate microarray results, we selected 9 FXR-regulated genes in the UNX dataset and quantified 16 
their expression by real-time PCR. All sqRT-PCR analyses were performed in samples previously used 17 
for microarray experiments. We found that both methods (microarray analysis and sqRT-PCR) yielded 18 
similar results regarding the increase and decrease in gene expression (Fig. 6). 19 
 20 
Next, we examined the immunostaining of kidney sections with specific antibodies against Actn1, Slco1a1, 21 
Slc27a4, TNFα and Cyp4a.  Figure 7 shows representative staining images of kidney sections from 22 
different treatment groups. Consistent with the changes in gene expression shown in Fig. 6 and Table 3, 23 
the staining of Actn1 (actinin, a cytoskeletal protein, 3.2-fold increase at the mRNA level) was increased in 24 
the cytoplasm of tubular cells (mostly proximal tubules) in the UNX-HFD group (Fig. 7A-7D); staining of 25 
Slc27a4 (fatty acid transporter 4, 1.9-fold increase at the mRNA level) was enhanced in the apical 26 
membrane of proximal tubules (indicated by arrows, Fig. 7I-7L); staining of TNFα (4.35-fold increase at 27 
the mRNA level) and Cyp4a14 (2.3-fold increase at the mRNA level) was increased in the cytoplasm of 28 
tubular cells (indicated by arrows, Fig. 7M-7P and 7Q-7T, respectively). In contrast, staining of Slco1a1 29 
(Oatp1a1, organic anion transporter that mediates the reuptake of organic anions, 0.36-fold decrease at 30 
mRNA level) was decreased in the apical membrane of proximal tubules in UNX-HFD kidney sections 31 
(Fig. 7E-7H). 32 
 33 
  34 
8 
 
4. Discussion 1 
 2 
An emerging body of evidence suggests that obesity is not only a risk factor for CKD, but also an 3 
independent cause of renal dysfunction. Glomerulosclerosis and progressive renal insufficiency have 4 
been reported in obese patients and experimental animals with a normal renal mass [5, 30]. Therefore, it 5 
is conceivable that renal damage due to obesity-related hyperfiltration is especially severe in conjunction 6 
with a reduction in renal mass. Studies on the relationship between reduced nephron number and 7 
susceptibility to obesity-related renal damage have suggested that obesity is associated with higher 8 
glomerular hyperfiltration [31] and higher risks of proteinuria and CKD [9, 32] in kidney donors. These 9 
observations led us to explore the mechanisms underlying renal insufficiency after renal mass reduction.  10 
We showed that obesity has marked effects on proteinuria, glomerular damage and interstitial fibrosis in 11 
mice fed a HFD, and these changes were further enhanced by uninephrectomy. Furthermore, gene 12 
profiling analysis and functional classification of differentially expressed genes in kidneys from each group 13 
revealed the synergistic effects of UNX and HFD on the expression of genes responsible for cytoskeletal 14 
morphogenesis, fibrosis and lipid metabolism. As a consequence, the function of the remnant kidney is 15 
more severely impaired. 16 
 17 
The gene profiling results are partly consistent with other studies analyzing gene expression in obesity-18 
related glomerulopathy in obese patients [17]. One important group of genes with a notable change in 19 
expression induced by the high fat diet involved lipid metabolism and transport, in both Sham-HFD and 20 
UNX-HFD groups. Disturbances in lipid metabolism are often observed in patients with chronic renal 21 
failure, and the negative impact of proteinuria on kidney disease progression could be mediated in part 22 
through the increased filtration of lipoproteins [33]. Network analysis showed that more genes involved in 23 
lipid transport and metabolism were affected in obese mice than in mice fed the chow diet (Table 3).  24 
Furthermore, several other networks were identified to be uniquely expressed in the UNX-HFD dataset, 25 
including cytoskeleton remodeling, cell-matrix adhesion and other genes involved in fibrogenesis. Thus, 26 
our microarray data are consistent with histological results which indicate that kidneys from UNX-HFD 27 
mice have a higher degree of mesangial matrix content and interstitial fibrosis. 28 
 29 
Pathway analysis implicated the Fxr signaling pathway as showing the strongest degree of activation in 30 
the remaining kidney of UNX-HFD mice. Fxr plays crucial roles in bile acid, cholesterol, lipid and glucose 31 
metabolism in the liver and intestine. In the liver, Fxr activation exerts antifibrotic effects by increasing the 32 
apoptosis of hepatic stellate cells [34]. However, the role of Fxr in kidney disease is still unclear. Fxr 33 
activation by potent agonists protects kidney function and limits renal fibrosis in diabetic and obese mice 34 
[35-37]. We previously showed that incubation of primary cultured rat renal proximal tubular cells with the 35 
FXR ligand chenodeoxycholic acid regulates the expression of bile acid transporters [38]. Moreover, 36 
exposure of hepatoma cells to bile acids decreased expression of hOATP1B1 (SLCO1B1) and hOAT2 37 
(SLC22A7) by an FXR-mediated mechanism [39, 40]. Here, we show decreased renal expression of the 38 
orthologous mouse genes Slco1b2 and Slc22a7 (Fig. 6), suggesting a conserved role of Fxr in regulating 39 
bile acid transport in the kidney. However, recent studies on Fxr null mice with bile duct ligation show that 40 
loss of Fxr in fact protects the kidney from cholemic nephropathy caused by high plasma bile acids [41].  41 
Future studies on kidney-specific Fxr knockout mice will be required to define the exact role of Fxr in 42 
obesity-induced kidney disease. 43 
 44 
Whereas some diets commonly used to induce alterations in lipid homeostasis and/or obesity contain 45 
cholic acid to enhance fat absorption, the high fat diet D12331 used in the present study (formula shown 46 
in Table S5) did not contain bile acids. Thus, the effects on Fxr signaling seen in the UNX-HFD mice were 47 
not induced by external bile acid administration. UNX-HFD mice had a tendency towards increased 48 
plasma bile acid levels, however this increase did not reach statistical significance by ANOVA analysis 49 
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(data not shown). Because HFD has been reported to contribute to a dysfunction of the lysosomal system 1 
and altered lipid metabolism, characterized by cholesterol and phospholipid accumulation in the kidney 2 
[42], we also measured kidney lipid composition in each group by thin layer chromatography. UNX-HFD 3 
kidney tissue had a tendency towards increased total phospholipid and cholesterol content, although the 4 
differences between groups did not reach statistical significance by ANOVA analysis (Supplementary Fig. 5 
1A-1D). 6 
 7 
Nephrectomy in man is generally considered to have a favorable long-term outcome. To what degree a 8 
reduced renal mass is safe may depend, however, on the general health condition [43]. Our study, among 9 
various similar studies in a large variety of models for hypertension, diabetes and kidney disease [29, 44, 10 
45], illustrates that in a diseased animal (including man), or in an animal model with increased glomerular 11 
capillary pressure, a reduction in renal mass is accompanied by an acceleration of renal disease. Taking 12 
into account the synergistic effects of obesity and UNX on the progression of renal insufficiency, 13 
avoidance of weight gain or weight loss in obese patients should be recommended to individuals with 14 
reduced renal mass [46-48]. Our results also have relevance in the setting of kidney donation, which 15 
results in a reduced renal mass and is being performed in an increasingly obese population [49]. 16 
 17 
In conclusion, we found that the effects of a HFD on the kidney appear to be accentuated in mice that 18 
have undergone uninephrectomy, as evidenced by accelerated progression of proteinuria and renal 19 
insufficiency 20 weeks after the procedure. This was also confirmed by the increased mesangial 20 
basement membrane area and the degree of renal fibrosis in the UNX-HFD mice. We thus show that 21 
uninephrectomy acts in synergism with HFD to promote changes in gene expression that are associated 22 
with renal damage and that activation of the FXR signaling pathway could be a protective mechanism in 23 
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Figure Captions 1 
 2 
Figure 1. Albuminuria and urinary H2O2 output in the four treatment groups. (A) Urine 3 
albumin/creatinine ratio increases with HFD at 20 weeks. (B) Urine H2O2/creatinine level is increased in 4 
mice fed with HFD for 20 weeks. Data are shown as mean ± SEM, * p < 0.05 5 
 6 
Figure 2. Histological analysis of remnant kidney tissue. Histological appearance of glomeruli in (A) 7 
Sham-chow mice, (B) UNX-chow mice, (C) Sham-HFD mice and (D) UNX-HFD mice. Representative 8 
images of (E to H) Masson trichrome-stained and (I to L) PAS stained renal sections of kidney tissues of 9 
(E and I) Sham-chow mice, (F and J) UNX-chow mice, (G and K) Sham-HFD mice and (H and L) UNX-10 
HFD mice. (M and N) Bars represent the quantitative analysis of (M) area of fibrosis and (N) area of 11 
mesangium where data are expressed as the mean ± SEM, * p < 0.05 12 
 13 
Figure 3. Microarray analysis of mRNA expression levels in kidney tissue of the four treatment 14 
groups. (A) Summary of differentially expressed genes between groups. Cut off 1.7-fold, p<0.05. (B) Plot 15 
sources of variation analysis indicates diet as the factor with the higher impact on gene expression 16 
among those four groups. Error indicates no impact on gene expression. Data were analyzed using Subio 17 
platform software. 18 
 19 
Figure 4. Comparison of common and distinct gene expression patterns across the different 20 
experimental conditions. (A) Venn diagram analysis of sham versus UNX datasets indicates that 1289 21 
genes (green) are commonly expressed in both sham-HFD and UNX-HFD kidneys, whereas 1152 and 22 
1292 genes are distinctly expressed in sham-HFD kidneys (blue) or UNX-HFD kidneys (orange), 23 
respectively. Data were analyzed using Subio platform software. (B) Gene ontology (GO) analysis of 24 
genes with a change in expression of ≥ 1.7 fold in kidney tissue of both Sham-HFD and UNX-HFD mice. 25 
Top 5 GO functional gene clusters are mostly involved in lipid transport and metabolism (green bars). (C) 26 
GO analysis of genes that showed a change of expression of ≥ 1.7 fold only in kidney tissue of UNX-HFD 27 
mice (orange bars). 28 
 29 
Figure 5. Network analysis of genes with a change of expression of ≥ 1.7 fold across treatment 30 
groups. The top 5 networks are listed. Green bars indicate genes with a change of expression level in 31 
kidneys of both Sham-HFD and UNX-HFD mice; genes that show altered expression exclusively in kidney 32 
tissue of either Sham-HFD or UNX-HFD mice are indicated by blue and orange bars, respectively. 33 
 34 
Figure 6. sqRT- PCR validation of microarray data. Changes in the expression level of FXR regulated 35 
genes as determined by microarray analysis (see Table 3) were reproducible by sqRT-PCR. Cyp4a14 is 36 
shown as a positive control for a HFD-induced increase in gene expression. Numbers shown in italics 37 
below gene names indicate the fold change in expression level detected by microarray (Table 3). Data are 38 
shown as mean ± SEM, * p < 0.05 39 
 40 
Figure 7. Immunohistochemistry staining of remnant kidney tissue for selected targets. Kidney 41 
paraffin sections from different treatment groups were immunostained with antibodies against Actn1 (A to 42 
D), Slco1a1 (E to H, decreased expression in UNX-HFD), Slc27a4 (I to L), TNFα (M to P) and Cyp4a14 43 
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Chow HFD Chow HFD 
Body weight (g) 35.5±0.6 53.2±1.5* 33.7±0.8 47.5±3.1* 





Plasma TG (mg/dl) 97.0±14.0 139.6±12.1* 102.1±7.7 148.6±9.3* 
Plasma Ch (mg/dl) 115.8±14.8 198.2±4.1* 109.4±5.8 177.9±15.5* 
 3 
Abbreviations: UNX, uninephrectomy; HFD, high fat diet. n=6 mice/group.  * p < 0.05, comparison 4 
between chow and HFD;  
§
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Table 2: Top 5 canonical pathways from UNX-HFD dataset 1 
 2 
Top 5 pathways by IPA  
(Ingenuity Pathway Analysis) 
Top 5 pathways by MetaCore
TM
 
Name p value Name p value 
FXR/RXR activation 3.11E-05 
WNT and cytoskeletal 
remodeling 
5.54E-08 






4.35E-03 Cytoskeleton remodeling 2.43E-04 
Androgen biosynthesis 4.4E-03 Cell-matrix glycoconjugates 1.02E-03 
Retinoate biosynthesis 5.26E-03 
Fxr regulated cholesterol and 
bile acid transport 
1.62E-03 
 3 
Differences in gene expression between UNX-HFD and UNX-chow groups were analyzed by IPA 4 
(Ingenuity Pathway Analysis) software and MetaCore
TM
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Table 3: Selected differentially expressed genes (≥1.7 fold) in 20-week remnant kidney of UNX-HFD 1 
mice grouped according to function 2 
 3 
Cytoskeleton remodeling 
Actn1 (1.69), Cfl1 (1.33), Mmp7(1.68), Cd44(0.85), Hrh4(0.85), Taok2(1.54), Rap1a (1.91), 
Prkd3 (0.82), Tesk2 (0.77), Actg1 (0.98), Tubb3(1.65), Parva (0.79), Pfn1 (0.94) 
Wnt signaling induced EMT (pro- fibrosis) 
Wnt1 (0.79), Wnt16 (0.98), Trp73(1.12), Adam17(1.36), Adam25(0.81), Lfng (1.59), Actn1 
(1.69), Actg1 (0.98), Dvl2 (0.96), Mmp7 (1.68) 
Lipid metabolism 
Abcb4 (-0.97), CYP2B10(-2.24), CYP2D10(-2.03), CYP3A59(-2.35), CYP4A32(1.16), 
Cyp7b1(-1.15), FOXO4(1.14), Mup1 (includes others), Nr1i3/Car(0.78), SLC1A6 (1.34), 
SLC27A4(0.95) 
Response to hypoxia 
Nppa (0.767), Ascl2 (0.8), Hpx (-3.54), Ece1 (0.85), Ccr6 (1.4), Ccr10 (1.07), Ppyr1 (0.95), 
Hif3a (1.39), Pklr (1.51), Kcna5 (1.42), Lep (2.63), Lepr (-0.84), P2rx2 (0.84), Pde7b (-0.82), 
Prkd3 (0.82), Pklr (1.51), Ramp1 (0.80), Ucp3 (1.26), Chrnb2 (0.84) 
Fxr regulated transporters 
Slco1a1 (-1.48), Slco1b2 (-2.53), Slc22a7 (-2.18), Abcb4 (-0.97) 
Salt and fluid retention 
Cyp4a14 (1.18), Slc4a4 (3.94), Slc9a3 (0.79) 
 4 
Numbers in parentheses indicate gene expression levels quantified as Log2 of fold changes: (1.69) 5 
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NAME Fold ChangeP-Value GENE_SYMBOLGENE_NAMEGO_ID
A_51_P4814821.761865 0.001945 Dram1 DNA-damage regulated autophagy modulator 1GO:0003674(m lecular_function)|GO:0005575(cellular_component)|GO:0005764(lysosome)|GO:0006914(autophagy)|GO:0006915(apoptotic process)|GO:0008150(biological_process)|GO:0016020(membrane)|GO:0016021(integral to membrane)
A_65_P076268.103457 0.00305
A_51_P4488561.839305 0.044903 Elf4 E74-like factor 4 (ets domain transcription factor)GO:0001787(natural killer cell proliferation)|GO:0001866(NK T cell proliferation)|GO:0003677(DNA binding)|GO:0003700(sequence-specific DNA binding transcription factor activity)|GO:0005634(nucleus)|GO:0006351(transcription, DNA-dependent)|GO:0006355(regulation of transcription, DNA-dependent)|GO:0016605(PML body)|GO:0043565(sequence-specific DNA binding)|GO:0045893(positive regulation of transcription, DNA-dependent)|GO:0045944(positive regulation of transcription from RNA polymerase II promoter)
A_55_P22519996.556071 0.010778 Mpp2 membrane protein, palmitoylated 2 (MAGUK p55 subfamily member 2)GO:0005515(protein binding)|GO:0009986(cell surface)|GO:0030165(PDZ domain binding)
A_55_P21768942.398375 0.02153
A_55_P2165234.817647 0.042214 2300005B03RikRIKEN cDNA 2300005B03 geneGO: 3674(molecular_function)|GO:0005575(cellular_component)|GO:0008150(biological_process)
A_55_P21452624.377593 1.92E-04 Pex5l peroxisomal biogenesis factor 5-likeGO:0000268(peroxisome targeting sequence binding)|GO:0005052(peroxisome matrix targeting signal-1 binding)|GO:0005221(intracellular cyclic nucleotide activated cation channel activity)|GO:0005515(protein binding)|GO:0005737(cytoplasm)|GO:0005778(peroxisomal membrane)|GO:0005829(cytosol)|GO:0016020(membrane)|GO:0016558(protein import into peroxisome matrix)|GO:0016560(protein import into peroxisome matrix, docking)|GO:0017071(intracellular cyclic nucleotide activated cation channel complex)|GO:0017137(Rab GTPase binding)|GO:0030425(dendrite)|GO:0031267(small GTPase binding)|GO:0042391(regulation of membrane potential)|GO:0043949(regulation of cAMP-mediated signaling)|GO:0045055(regulated secretory pathway)|GO:0045185(maintenance of protein location)|GO:0048471(perinuclear region of cytoplasm)|GO:0051286(cell tip)|GO:0051461(positive regulation of corticotropin secretion)
A_55_P20022263.848433 0.017959 Dzip1 DAZ interacting protein 1GO:0005515(protein binding)|GO:0005622(intracellular)|GO:0005634(nucleus)|GO:0005737(cytoplasm)|GO:0007275(multicellular organismal development)|GO:0007283(spermatogenesis)|GO:0008270(zinc ion binding)|GO:0030154(cell differentiation)|GO:0036064(cilium basal body)|GO:0042384(cilium assembly)|GO:0046872(metal ion binding)
A_55_P20889052.921548 0.003579 Hpca hippocalcinGO:0003779(actin binding)|GO:0005509(calcium ion binding)|GO:0005515(protein binding)|GO:0046872(metal ion binding)|GO:0048839(inner ear development)
A_55_P22831163.445533 0.002752 4930478P22RikRIKEN cDNA 4930478P22 gene
A_55_P21860252.556891 0.001853
A_52_P6835801.827733 0.002737 Tbc1d9 TBC1 domain family, member 9GO:0003674( olecular_function)|GO:0005096(GTPase activator activity)|GO:0005097(Rab GTPase activator activity)|GO:0005509(calcium ion binding)|GO:0005575(cellular_component)|GO:0005622(intracellular)|GO:0008150(biological_process)|GO:0032313(regulation of Rab GTPase activity)
A_66_P132825.814476 8.64E-04
A_55_P21072391.816696 0.028917 Ggn gametogenetinGO:0005515(protein binding)|GO:0005634(nucleus)|GO:0005635(nuclear envelope)|GO:0005730(nucleolus)|GO:0005737(cytoplasm)|GO:0006461(protein complex assembly)|GO:0007275(multicellular organismal development)|GO:0007283(spermatogenesis)|GO:0008104(protein localization)|GO:0016021(integral to membrane)|GO:0030154(cell differentiation)|GO:0031410(cytoplasmic vesicle)|GO:0046983(protein dimerization activity)|GO:0048471(perinuclear region of cytoplasm)
A_51_P1355173.357786 0.008657 Coch coagulation factor C homolog (Limulus polyphemus)GO:0003674(m lecular_function)|GO:0005575(cellular_component)|GO:0005576(extracellular region)|GO:0007605(sensory perception of sound)|GO:0008360(regulation of cell shape)
A_55_P21730112.064302 0.00834 Nfasc neurofascinGO:0002175(protein localization to paranode region of axon)|GO:0005622(intracellular)|GO:0005886(plasma membrane)|GO:0007155(cell adhesion)|GO:0007411(axon guidance)|GO:0007422(peripheral nervous system development)|GO:0016020(membrane)|GO:0016021(integral to membrane)|GO:0019226(transmission of nerve impulse)|GO:0030424(axon)|GO:0030913(paranodal junction assembly)|GO:0033010(paranodal junction)|GO:0033268(node of Ranvier)|GO:0033270(paranode region of axon)|GO:0042552(myelination)|GO:0043194(initial segment)|GO:0045162(clustering of voltage-gated sodium channels)|GO:0050808(synapse organization)|GO:0071205(protein localization to juxtaparanode region of axon)|GO:0072661(protein targeting to plasma membrane)|GO:0086080(protein binding involved in heterotypic cell-cell adhesion)
A_55_P20215701.831174 0.020929 C87414 expressed sequence C87414GO:0003674(molecular_function)|GO:0005575(cellular_component)|GO:0008150(biological_process)
A_52_P2232694.00476 4.47E-04 Zfp37 zinc finger protein 37GO:000 676(nucleic acid binding)|GO:0003677(DNA binding)|GO:0005622(intracellular)|GO:0005634(nucleus)|GO:0006351(transcription, DNA-dependent)|GO:0006355(regulation of transcription, DNA-dependent)|GO:0007275(multicellular organismal development)|GO:0007281(germ cell development)|GO:0007283(spermatogenesis)|GO:0008270(zinc ion binding)|GO:0030154(cell differentiation)|GO:0046872(metal ion binding)
A_52_P4875991.946543 0.002308 Thnsl2 threonine synthase-like 2 (bacterial)GO:0004795(threonine synthase activity)|GO:0005575(cellular_component)|GO:0008152(metabolic process)|GO:0009071(serine family amino acid catabolic process)|GO:0009088(threonine biosynthetic process)|GO:0016311(dephosphorylation)|GO:0016829(lyase activity)|GO:0030170(pyridoxal phosphate binding)|GO:0046360(2-oxobutyrate biosynthetic process)|GO:0070905(serine binding)
A_51_P293982.06703 0.042471 Plekho2 pleckstrin homology domain containing, family O member 2GO:0003674(molecular_function)|G :0005543(phospholipid binding)|GO:0005575(cellular_component)|GO:0008150(biological_process)
A_55_P2140195.927308 0.006145
A_55_P20676291.823752 0.007865 Ush1g Usher syndrome 1GGO:0005515(protein binding)|GO:0005737(cytoplasm)|GO:0005856(cytoskeleton)|GO:0005886(plasma membrane)|GO:0007605(sensory perception of sound)|GO:0015629(actin cytoskeleton)|GO:0016020(membrane)|GO:0042472(inner ear morphogenesis)|GO:0042803(protein homodimerization activity)|GO:0045494(photoreceptor cell maintenance)|GO:0050953(sensory perception of light stimulus)|GO:0050957(equilibrioception)|GO:0060113(inner ear receptor cell differentiation)
A_55_P20685102.078934 0.029772 Defa1 defensin, alpha 1GO:0005576(extracellular region)|GO:0005615(extracellular space)|GO:0006952(defense response)|GO:0042493(response to drug)|GO:0042742(defense response to bacterium)|GO:0050829(defense response to Gram-negative bacterium)|GO:0050830(defense response to Gram-positive bacterium)|GO:0071222(cellular response to lipopolysaccharide)
A_55_P20093451.778136 0.002865 Ovch2 ovochymase 2GO:0003824(catalytic activity)|GO:0004252(serine-type endopeptidase activity)|GO:0005575(cellular_component)|GO:0005576(extracellular region)|GO:0006508(proteolysis)|GO:0008233(peptidase activity)|GO:0008236(serine-type peptidase activity)|GO:0016787(hydrolase activity)|GO:0046872(metal ion binding)
A_51_P2429301.746102 0.00591 Lat2 linker for activation of T cells family, member 2GO:0005622(intracellular)|GO:0005886(plasma membrane)|GO:0016020(membrane)|GO:0016021(integral to membrane)|GO:0019722(calcium-mediated signaling)|GO:0035556(intracellular signal transduction)|GO:0042113(B cell activation)|GO:0042169(SH2 domain binding)|GO:0043303(mast cell degranulation)|GO:0045121(membrane raft)|GO:0050853(B cell receptor signaling pathway)
A_52_P809443.053202 0.03286 Zfp36 zinc finger protein 36GO:0000122(negative regulation of transcription from RNA polymerase II promoter)|GO:0000288(nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay)|GO:0000289(nuclear-transcribed mRNA poly(A) tail shortening)|GO:0003676(nucleic acid binding)|GO:0003677(DNA binding)|GO:0003729(mRNA binding)|GO:0005634(nucleus)|GO:0005737(cytoplasm)|GO:0005829(cytosol)|GO:0006357(regulation of transcription from RNA polymerase II promoter)|GO:0006402(mRNA catabolic process)|GO:0006950(response to stress)|GO:0007243(intracellular protein kinase cascade)|GO:0008270(zinc ion binding)|GO:0010494(cytoplasmic stress granule)|GO:0017091(AU-rich element binding)|GO:0019901(protein kinase binding)|GO:0019957(C-C chemokine binding)|GO:0032680(regulation of tumor necrosis factor production)|GO:0035925(mRNA 3'-UTR AU-rich region binding)|GO:0043488(regulation of mRNA stability)|GO:0045638(negative regulation of myeloid cell differentiation)|GO:0046872(metal ion binding)|GO:0050728(negative regulation of inflammatory resp
A_55_P20645721.776402 0.00353 Fgd5 FYVE, RhoGEF and PH domain containing 5GO:0003674( ole ular_fu ction)|GO:0005085(guanyl-nucleotide exchange factor activity)|GO:0005089(Rho guanyl-nucleotide exchange factor activity)|GO:0005543(phospholipid binding)|GO:0005575(cellular_component)|GO:0005622(intracellular)|GO:0005737(cytoplasm)|GO:0005768(endosome)|GO:0005783(endoplasmic reticulum)|GO:0005794(Golgi apparatus)|GO:0005856(cytoskeleton)|GO:0005886(plasma membrane)|GO:0008150(biological_process)|GO:0016020(membrane)|GO:0035023(regulation of Rho protein signal transduction)|GO:0042995(cell projection)|GO:0046872(metal ion binding)
A_52_P5367962.145072 0.005903 Hpgds hematopoietic prostaglandin D synthaseGO:0000287(magne ium ion binding)|GO:0001516(prostaglandin biosynthetic process)|GO:0004364(glutathione transferase activity)|GO:0004667(prostaglandin-D synthase activity)|GO:0005509(calcium ion binding)|GO:0005634(nucleus)|GO:0005737(cytoplasm)|GO:0006629(lipid metabolic process)|GO:0006631(fatty acid metabolic process)|GO:0006633(fatty acid biosynthetic process)|GO:0006693(prostaglandin metabolic process)|GO:0016740(transferase activity)|GO:0016853(isomerase activity)|GO:0042803(protein homodimerization activity)
A_51_P3417362.14183 0.030757 Mmp2 matrix metallopeptidase 2GO:0001525(angiogenesis)|GO:0001541(ovarian follicle development)|GO:0001666(response to hypoxia)|GO:0001955(blood vessel maturation)|GO:0001957(intramembranous ossification)|GO:0001968(fibronectin binding)|GO:0004222(metalloendopeptidase activity)|GO:0005576(extracellular region)|GO:0005578(proteinaceous extracellular matrix)|GO:0005615(extracellular space)|GO:0005634(nucleus)|GO:0005737(cytoplasm)|GO:0005886(plasma membrane)|GO:0006508(proteolysis)|GO:0006979(response to oxidative stress)|GO:0007162(negative regulation of cell adhesion)|GO:0007566(embryo implantation)|GO:0008152(metabolic process)|GO:0008233(peptidase activity)|GO:0008237(metallopeptidase activity)|GO:0008270(zinc ion binding)|GO:0009612(response to mechanical stimulus)|GO:0014012(peripheral nervous system axon regeneration)|GO:0016020(membrane)|GO:0016477(cell migration)|GO:0016787(hydrolase activity)|GO:0030017(sarcomere)|GO:0030574(collagen catabolic process)|GO:0031012(extracellular matrix)|GO:0042493(response to drug)|GO:0042542(respon
A_55_P20485602.051177 3.70E-05 Smn1 survival motor neuron 1GO:0003723(RNA binding)|GO:0005634(nucleus)|GO:0005681(spliceosomal complex)|GO:0005730(nucleolus)|GO:0005737(cytoplasm)|GO:0006397(mRNA processing)|GO:0007019(microtubule depolymerization)|GO:0007409(axonogenesis)|GO:0008380(RNA splicing)|GO:0015030(Cajal body)|GO:0017134(fibroblast growth factor binding)
A_55_P20258704.154113 0.01021 Ccdc169 coiled-coil domain containing 169GO:0003674(molecular_function)|GO:0005575(cellular_component)|GO:0008150(biological_process)
A_55_P23784861.994081 0.020853 Kcnma1 potassium large conductance calcium-activated channel, subfamily M, alpha member 1GO:0000166(nucleotide binding)|GO:0001666(response to hypoxia)|GO:0003779(actin binding)|GO:0005216(ion channel activity)|GO:0005244(voltage-gated ion channel activity)|GO:0005249(voltage-gated potassium channel activity)|GO:0005267(potassium channel activity)|GO:0005515(protein binding)|GO:0005783(endoplasmic reticulum)|GO:0005886(plasma membrane)|GO:0005901(caveola)|GO:0006810(transport)|GO:0006811(ion transport)|GO:0006813(potassium ion transport)|GO:0006970(response to osmotic stress)|GO:0007268(synaptic transmission)|GO:0007605(sensory perception of sound)|GO:0007623(circadian rhythm)|GO:0007628(adult walking behavior)|GO:0008076(voltage-gated potassium channel complex)|GO:0009268(response to pH)|GO:0009897(external side of plasma membrane)|GO:0015269(calcium-activated potassium channel activity)|GO:0016020(membrane)|GO:0016021(integral to membrane)|GO:0016324(apical plasma membrane)|GO:0019031(viral envelope)|GO:0019228(regulation of action potential in neuron)|GO:0030007(cellular potassium ion homeosta
A_51_P4271712.558353 0.001334 Lacc1 laccase (multicopper oxidoreductase) domain containing 1GO:0003674(molecular_function)|GO:0005575(cellular_component)|GO:0008150(biological_process)
A_52_P1189581.903089 0.002617 Pex19 peroxisomal biogenesis factor 19GO:0005515(protein binding)|GO:0005634(nucleus)|GO:0005737(cytoplasm)|GO:0005777(peroxisome)|GO:0005778(peroxisomal membrane)|GO:0005829(cytosol)|GO:0006625(protein targeting to peroxisome)|GO:0007031(peroxisome organization)|GO:0016020(membrane)|GO:0016021(integral to membrane)|GO:0016557(peroxisome membrane biogenesis)|GO:0016559(peroxisome fission)|GO:0031526(brush border membrane)|GO:0036105(peroxisome membrane class-1 targeting sequence binding)|GO:0043234(protein complex)|GO:0045046(protein import into peroxisome membrane)|GO:0047485(protein N-terminus binding)|GO:0050821(protein stabilization)|GO:0051117(ATPase binding)|GO:0061077(chaperone-mediated protein folding)|GO:0072321(chaperone-mediated protein transport)|GO:0072663(establishment of protein localization to peroxisome)|GO:1900131(negative regulation of lipid binding)
A_51_P3896642.323341 6.58E-04 Scrt2 scratch homolog 2, zinc finger protein (Drosophila)GO:0003676(nucleic acid binding)|GO:0003677(DNA binding)|GO:0005622(intracellular)|GO:0005634(nucleus)|GO:0006351(transcription, DNA-dependent)|GO:0006355(regulation of transcription, DNA-dependent)|GO:0008150(biological_process)|GO:0008270(zinc ion binding)|GO:0046872(metal ion binding)
A_55_P19616502.427879 0.005664
A_55_P19573932.40682 0.002187
A_55_P20332781.927606 0.009197 Speer5-ps1 spermatogenesis associated glutamate (E)-rich protein 5, pseudogene 1
A_52_P5231742.352239 0.005006 Sh2d6 SH2 domain containing 6GO:0003674(molecular_function)|GO:0005575(cellular_component)|GO:0008150(biological_process)
A_55_P21630903.301989 0.039021 Gm10220 predicted gene 10220GO:0 03674(molecular_function)|GO:0005575(cellular_component)|GO:0008150(biological_process)
A_55_P21516462.062939 0.020058 Mcm9 minichromosome maintenance complex component 9GO:0000166( ucleotide binding)|GO:0000724(double-strand break repair via homologous recombination)|GO:0003674(molecular_function)|GO:0003677(DNA binding)|GO:0004386(helicase activity)|GO:0005524(ATP binding)|GO:0005634(nucleus)|GO:0006260(DNA replication)|GO:0006281(DNA repair)|GO:0006974(response to DNA damage stimulus)|GO:0007276(gamete generation)|GO:0007292(female gamete generation)|GO:0016787(hydrolase activity)|GO:0017111(nucleoside-triphosphatase activity)
A_55_P20135692.068399 0.005047 Agbl4 ATP/GTP binding protein-like 4GO:0004180(carboxypeptidase activity)|GO:0004181(metallocarboxypeptidase activity)|GO:0005515(protein binding)|GO:0005737(cytoplasm)|GO:0005829(cytosol)|GO:0006508(proteolysis)|GO:0008233(peptidase activity)|GO:0008237(metallopeptidase activity)|GO:0008270(zinc ion binding)|GO:0015631(tubulin binding)|GO:0016787(hydrolase activity)|GO:0035609(C-terminal protein deglutamylation)|GO:0035610(protein side chain deglutamylation)|GO:0046872(metal ion binding)
A_55_P21220751.7195 0.003445 Pdcd1lg2 programmed cell death 1 ligand 2GO:0005515(protein binding)|GO:0005886(plasma membrane)|GO:0016020(membrane)|GO:0016021(integral to membrane)|GO:0042102(positive regulation of T cell proliferation)|GO:0042130(negative regulation of T cell proliferation)
A_55_P19983892.171455 0.009334
A_66_P1295642.49522 0.023319 Ngb neuroglobinGO:0005344(oxygen transporter activity)|GO:0005506(iron ion binding)|GO:0005737(cytoplasm)|GO:0005739(mitochondrion)|GO:0006810(transport)|GO:0006915(apoptotic process)|GO:0015671(oxygen transport)|GO:0019825(oxygen binding)|GO:0020037(heme binding)|GO:0046872(metal ion binding)
A_55_P19556024.146521 0.002995
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NAME Fold ChangeP-Value GENE_SYMBOLGENE_NAMEGO_ID
A_65_P076268.307668 0.010207
A_55_P21652343.722401 0.001399 2300005B03RikRIKEN cDNA 2300005B03 geneGO: 3674(molecular_function)|GO:0005575(cellular_component)|GO:0008150(biological_process)
A_55_P21768942.533281 0.001827
A_55_P20022263.672292 0.003 Dzip1 DAZ interacting protein 1GO:0005515(protein binding)|GO:0005622(intracellular)|GO:0005634(nucleus)|GO:0005737(cytoplasm)|GO:0007275(multicellular organismal development)|GO:0007283(spermatogenesis)|GO:0008270(zinc ion binding)|GO:0030154(cell differentiation)|GO:0036064(cilium basal body)|GO:0042384(cilium assembly)|GO:0046872(metal ion binding)
A_55_P2145262.597939 0.003074 Pex5l peroxisomal biogenesis factor 5-likeGO:0000268(peroxisome targeting sequence binding)|GO:0005052(peroxisome matrix targeting signal-1 binding)|GO:0005221(intracellular cyclic nucleotide activated cation channel activity)|GO:0005515(protein binding)|GO:0005737(cytoplasm)|GO:0005778(peroxisomal membrane)|GO:0005829(cytosol)|GO:0016020(membrane)|GO:0016558(protein import into peroxisome matrix)|GO:0016560(protein import into peroxisome matrix, docking)|GO:0017071(intracellular cyclic nucleotide activated cation channel complex)|GO:0017137(Rab GTPase binding)|GO:0030425(dendrite)|GO:0031267(small GTPase binding)|GO:0042391(regulation of membrane potential)|GO:0043949(regulation of cAMP-mediated signaling)|GO:0045055(regulated secretory pathway)|GO:0045185(maintenance of protein location)|GO:0048471(perinuclear region of cytoplasm)|GO:0051286(cell tip)|GO:0051461(positive regulation of corticotropin secretion)
A_55_P21503982.153574 7.91E-04 Cpne5 copine V GO:0003674(molecular_function)|GO:0008150(biological_process)|GO:0043005(neuron projection)|GO:0043025(neuronal cell body)
A_55_P21072391.778609 0.001725 Ggn gametogenetinGO:0005515(protein binding)|GO:0005634(nucleus)|GO:0005635(nuclear envelope)|GO:0005730(nucleolus)|GO:0005737(cytoplasm)|GO:0006461(protein complex assembly)|GO:0007275(multicellular organismal development)|GO:0007283(spermatogenesis)|GO:0008104(protein localization)|GO:0016021(integral to membrane)|GO:0030154(cell differentiation)|GO:0031410(cytoplasmic vesicle)|GO:0046983(protein dimerization activity)|GO:0048471(perinuclear region of cytoplasm)
A_55_P21730112.018861 4.41E-04 Nfasc neurofascinGO:0002175(protein localization to paranode region of axon)|GO:0005622(intracellular)|GO:0005886(plasma membrane)|GO:0007155(cell adhesion)|GO:0007411(axon guidance)|GO:0007422(peripheral nervous system development)|GO:0016020(membrane)|GO:0016021(integral to membrane)|GO:0019226(transmission of nerve impulse)|GO:0030424(axon)|GO:0030913(paranodal junction assembly)|GO:0033010(paranodal junction)|GO:0033268(node of Ranvier)|GO:0033270(paranode region of axon)|GO:0042552(myelination)|GO:0043194(initial segment)|GO:0045162(clustering of voltage-gated sodium channels)|GO:0050808(synapse organization)|GO:0071205(protein localization to juxtaparanode region of axon)|GO:0072661(protein targeting to plasma membrane)|GO:0086080(protein binding involved in heterotypic cell-cell adhesion)
A_52_P4875991.781307 0.001765 Thnsl2 threonine synthase-like 2 (bacterial)GO:0004795(threonine synthase activity)|GO:0005575(cellular_component)|GO:0008152(metabolic process)|GO:0009071(serine family amino acid catabolic process)|GO:0009088(threonine biosynthetic process)|GO:0016311(dephosphorylation)|GO:0016829(lyase activity)|GO:0030170(pyridoxal phosphate binding)|GO:0046360(2-oxobutyrate biosynthetic process)|GO:0070905(serine binding)
A_55_P20676291.755812 0.001707 Ush1g Usher syndrome 1GGO:0005515(protein binding)|GO:0005737(cytoplasm)|GO:0005856(cytoskeleton)|GO:0005886(plasma membrane)|GO:0007605(sensory perception of sound)|GO:0015629(actin cytoskeleton)|GO:0016020(membrane)|GO:0042472(inner ear morphogenesis)|GO:0042803(protein homodimerization activity)|GO:0045494(photoreceptor cell maintenance)|GO:0050953(sensory perception of light stimulus)|GO:0050957(equilibrioception)|GO:0060113(inner ear receptor cell differentiation)
A_55_P2140195.916453 6.81E-04
A_52_P6099722.420619 0.037332 Eln elastin GO:0001974(blood vessel remodeling)|GO:0005201(extracellular matrix structural constituent)|GO:0005515(protein binding)|GO:0005576(extracellular region)|GO:0005578(proteinaceous extracellular matrix)|GO:0005739(mitochondrion)|GO:0007519(skeletal muscle tissue development)|GO:0030023(extracellular matrix constituent conferring elasticity)|GO:0030198(extracellular matrix organization)|GO:0030833(regulation of actin filament polymerization)|GO:0043149(stress fiber assembly)|GO:0050840(extracellular matrix binding)|GO:0071953(elastic fiber)
A_55_P20258703.849947 0.005937 Ccdc169 coiled-coil domain containing 169GO:0003674(molecular_function)|GO:0005575(cellular_component)|GO:0008150(biological_process)
A_51_P3896642.134217 8.76E-04 Scrt2 scratch homolog 2, zinc finger protein (Drosophila)GO:0003676(nucleic acid binding)|GO:0003677(DNA binding)|GO:0005622(intracellular)|GO:0005634(nucleus)|GO:0006351(transcription, DNA-dependent)|GO:0006355(regulation of transcription, DNA-dependent)|GO:0008150(biological_process)|GO:0008270(zinc ion binding)|GO:0046872(metal ion binding)
A_51_P1931732.57158 2.35E-04 Slc25a25 solute carrier family 25 (mitochondrial carrier, phosphate carrier), member 25GO:0005509(calcium ion binding)|GO:0005739(mitochondrion)|GO:0005743(mitochondrial inner membrane)|GO:0006810(transport)|GO:0008150(biological_process)|GO:0016020(membrane)|GO:0016021(integral to membrane)|GO:0046872(metal ion binding)|GO:0055085(transmembrane transport)
A_55_P2185185.992609 5.60E-04 Tmem28 transmembrane protein 28GO:0003674(molecular_function)|GO:0005575(cellular_component)|GO:0008150(biological_process)|GO:0016020(membrane)|GO:0016021(integral to membrane)




A_55_P22680221.996629 0.008285 9330199G10RikRIKEN cDNA 9330199G10 gene
A_51_P3485921.804534 0.035817 Slc38a7 solute carrier family 38, member 7GO:0005290(L-histidine transmembrane transporter activity)|GO:0005313(L-glutamate transmembrane transporter activity)|GO:0006810(transport)|GO:0006811(ion transport)|GO:0006814(sodium ion transport)|GO:0006865(amino acid transport)|GO:0015179(L-amino acid transmembrane transporter activity)|GO:0015180(L-alanine transmembrane transporter activity)|GO:0015182(L-asparagine transmembrane transporter activity)|GO:0015183(L-aspartate transmembrane transporter activity)|GO:0015186(L-glutamine transmembrane transporter activity)|GO:0015190(L-leucine transmembrane transporter activity)|GO:0015191(L-methionine transmembrane transporter activity)|GO:0015194(L-serine transmembrane transporter activity)|GO:0016020(membrane)|GO:0016021(integral to membrane)|GO:0030424(axon)|GO:0034220(ion transmembrane transport)|GO:0043025(neuronal cell body)
A_55_P19888722.872486 0.011269 Bcl11a B cell CLL/lymphoma 11A (zinc finger protein)GO:0003676(nucleic acid binding)|GO:0003714(transcription corepressor activity)|GO:0005515(protein binding)|GO:0005622(intracellular)|GO:0005634(nucleus)|GO:0005737(cytoplasm)|GO:0006351(transcription, DNA-dependent)|GO:0006355(regulation of transcription, DNA-dependent)|GO:0008270(zinc ion binding)|GO:0010629(negative regulation of gene expression)|GO:0010976(positive regulation of neuron projection development)|GO:0010977(negative regulation of neuron projection development)|GO:0016604(nuclear body)|GO:0016925(protein sumoylation)|GO:0030183(B cell differentiation)|GO:0030217(T cell differentiation)|GO:0046872(metal ion binding)|GO:0046982(protein heterodimerization activity)|GO:0048671(negative regulation of collateral sprouting)|GO:0048672(positive regulation of collateral sprouting)|GO:0050773(regulation of dendrite development)|GO:2000171(negative regulation of dendrite development)
A_55_P21350643.956673 0.030769 H2-M2 histocompatibility 2, M region locus 2GO:0003674(molecular_function)|GO:0008150(biological_process)|GO:0009986(cell surface)
A_52_P680283.24088 0.021368 Ace angiotensin I converting enzyme (peptidyl-dipeptidase A) 1GO:0001822(kidney development)|GO:0002446(neutrophil mediated immunity)|GO:0003084(positive regulation of systemic arterial blood pressure)|GO:0003779(actin binding)|GO:0004175(endopeptidase activity)|GO:0004180(carboxypeptidase activity)|GO:0005576(extracellular region)|GO:0005615(extracellular space)|GO:0005768(endosome)|GO:0005886(plasma membrane)|GO:0006508(proteolysis)|GO:0006518(peptide metabolic process)|GO:0007283(spermatogenesis)|GO:0008144(drug binding)|GO:0008152(metabolic process)|GO:0008217(regulation of blood pressure)|GO:0008233(peptidase activity)|GO:0008237(metallopeptidase activity)|GO:0008241(peptidyl-dipeptidase activity)|GO:0008270(zinc ion binding)|GO:0009897(external side of plasma membrane)|GO:0014910(regulation of smooth muscle cell migration)|GO:0016020(membrane)|GO:0016021(integral to membrane)|GO:0016787(hydrolase activity)|GO:0019233(sensory perception of pain)|GO:0031100(organ regeneration)|GO:0031404(chloride ion binding)|GO:0031711(bradykinin receptor binding)|GO:0032496(respon
A_55_P20687841.990991 0.034442 Colq collagen-like tail subunit (single strand of homotrimer) of asymmetric acetylcholinesteraseGO:0005581(collagen)|GO:0008201(heparin binding)|GO:0030054(cell junction)|GO:0042135(neurotransmitter catabolic process)|GO:0045202(synapse)
A_55_P20869042.234258 0.002157
A_51_P4389674.210516 0.012624 Gpnmb glycoprotein (transmembrane) nmbGO:0005178(integri  binding)|GO:0005887(integral to plasma membrane)|GO:0007155(cell adhesion)|GO:0008201(heparin binding)|GO:0016020(membrane)|GO:0016021(integral to membrane)|GO:0016023(cytoplasmic membrane-bounded vesicle)|GO:0031410(cytoplasmic vesicle)
A_55_P20325181.882102 0.019196 Slc5a4a solute carrier family 5, member 4aGO:0005215(transporter activity)|GO:0006810(transport)|GO:0006811(ion transport)|GO:0006814(sodium ion transport)|GO:0008643(carbohydrate transport)|GO:0015078(hydrogen ion transmembrane transporter activity)|GO:0015293(symporter activity)|GO:0015992(proton transport)|GO:0016020(membrane)|GO:0016021(integral to membrane)|GO:0055085(transmembrane transport)
A_55_P21787209.622099 2.87E-06
A_55_P21047692.368195 1.26E-04 Utf1 undifferentiated embryonic cell transcription factor 1GO:0003713(transcription coactivator activity)|GO:0005515(protein binding)|GO:0005634(nucleus)|GO:0006351(transcription, DNA-dependent)|GO:0006355(regulation of transcription, DNA-dependent)|GO:0045944(positive regulation of transcription from RNA polymerase II promoter)|GO:0071837(HMG box domain binding)
A_51_P1065911.706934 0.026615 Celf3 CUGBP, Elav-like family member 3GO:0000166(nucleotide binding)|GO:0000381(regulation of alternative nuclear mRNA splicing, via spliceosome)|GO:0003676(nucleic acid binding)|GO:0003723(RNA binding)|GO:0005634(nucleus)|GO:0005737(cytoplasm)|GO:0006397(mRNA processing)|GO:0007283(spermatogenesis)|GO:0008380(RNA splicing)|GO:0030317(sperm motility)|GO:0048026(positive regulation of nuclear mRNA splicing, via spliceosome)
A_66_P1071291.711738 0.049891 3300005D01RikRIKEN cDNA 3300005D01 gene
A_51_P341918.972925 2.97E-05 Tsc22d1 TSC22 domain family, member 1GO:0003700(sequence-specific DNA binding transcription factor activity)|GO:0005634(nucleus)|GO:0005737(cytoplasm)|GO:0006351(transcription, DNA-dependent)|GO:0006355(regulation of transcription, DNA-dependent)|GO:0008284(positive regulation of cell proliferation)|GO:0043065(positive regulation of apoptotic process)|GO:0043066(negative regulation of apoptotic process)
A_51_P1025183.309079 7.97E-05 Tmem225 transmembrane protein 225GO:0003674(molecular_function)|GO:0005575(cellular_component)|GO:0010923(negative regulation of phosphatase activity)|GO:0016020(membrane)|GO:0016021(integral to membrane)
A_51_P2767153.36924 1.05E-04 Olfr1350 olfactory receptor 1350GO:0004871(signal transducer activity)|GO:0004930(G-protein coupled receptor activity)|GO:0004984(olfactory receptor activity)|GO:0005886(plasma membrane)|GO:0007165(signal transduction)|GO:0007186(G-protein coupled receptor signaling pathway)|GO:0007608(sensory perception of smell)|GO:0016020(membrane)|GO:0016021(integral to membrane)|GO:0050896(response to stimulus)
A_55_P19640332.140484 0.032632 Carm1 coactivator-associated arginine methyltransferase 1GO:0003420(regulation of g owth plate cartilage chondrocyte proliferation)|GO:0003713(transcription coactivator activity)|GO:0005515(protein binding)|GO:0005634(nucleus)|GO:0005737(cytoplasm)|GO:0005829(cytosol)|GO:0006351(transcription, DNA-dependent)|GO:0006355(regulation of transcription, DNA-dependent)|GO:0006479(protein methylation)|GO:0008168(methyltransferase activity)|GO:0008276(protein methyltransferase activity)|GO:0008284(positive regulation of cell proliferation)|GO:0008469(histone-arginine N-methyltransferase activity)|GO:0009405(pathogenesis)|GO:0016274(protein-arginine N-methyltransferase activity)|GO:0016568(chromatin modification)|GO:0016571(histone methylation)|GO:0016740(transferase activity)|GO:0019919(peptidyl-arginine methylation, to asymmetrical-dimethyl arginine)|GO:0030374(ligand-dependent nuclear receptor transcription coactivator activity)|GO:0030518(intracellular steroid hormone receptor signaling pathway)|GO:0030520(intracellular estrogen receptor signaling pathway)|GO:0032091(neg
A_55_P21144372.162356 0.003166 Pvalb parvalbuminGO:0005509(calcium ion binding)|GO:0005634(nucleus)|GO:0005737(cytoplasm)|GO:0030424(axon)|GO:0042803(protein homodimerization activity)|GO:0043234(protein complex)|GO:0046872(metal ion binding)|GO:0046982(protein heterodimerization activity)|GO:0051480(cytosolic calcium ion homeostasis)
A_55_P19713731.905833 0.001541 Nlrp12 NLR family, pyrin domain containing 12GO:0000166(nucleotide binding)|GO:0003674(molecular_function)|GO:0005524(ATP binding)|GO:0005634(nucleus)|GO:0005737(cytoplasm)|GO:0008588(release of cytoplasmic sequestered NF-kappaB)|GO:0009968(negative regulation of signal transduction)|GO:0031953(negative regulation of protein autophosphorylation)|GO:0032088(negative regulation of NF-kappaB transcription factor activity)|GO:0043122(regulation of I-kappaB kinase/NF-kappaB cascade)|GO:0043124(negative regulation of I-kappaB kinase/NF-kappaB cascade)|GO:0043281(regulation of cysteine-type endopeptidase activity involved in apoptotic process)|GO:0045345(positive regulation of MHC class I biosynthetic process)|GO:0045409(negative regulation of interleukin-6 biosynthetic process)|GO:0045751(negative regulation of Toll signaling pathway)|GO:0050710(negative regulation of cytokine secretion)|GO:0050711(negative regulation of interleukin-1 secretion)|GO:0050728(negative regulation of inflammatory response)
A_55_P2109392.691839 3.89E-04 Scn11a sodium channel, voltage-gated, type XI, alphaGO:0001518(voltage-gated sodium channel complex)|GO:0005216(ion channel activity)|GO:0005244(voltage-gated ion channel activity)|GO:0005248(voltage-gated sodium channel activity)|GO:0005272(sodium channel activity)|GO:0005515(protein binding)|GO:0005886(plasma membrane)|GO:0006810(transport)|GO:0006811(ion transport)|GO:0006814(sodium ion transport)|GO:0016020(membrane)|GO:0016021(integral to membrane)|GO:0030424(axon)|GO:0034220(ion transmembrane transport)|GO:0034765(regulation of ion transmembrane transport)|GO:0035725(sodium ion transmembrane transport)|GO:0044299(C-fiber)|GO:0055085(transmembrane transport)
A_55_P21282201.96411 0.00218 GO:0000079(regulation of cyclin-dependent protein kinase activity)|GO:0000166(nucleotide binding)|GO:0004672(protein kinase activity)|GO:0004674(protein serine/threonine kinase activity)|GO:0004693(cyclin-dependent protein kinase activity)|GO:0004702(receptor signaling protein serine/threonine kinase activity)|GO:0004713(protein tyrosine kinase activity)|GO:0005524(ATP binding)|GO:0005634(nucleus)|GO:0005675(holo TFIIH complex)|GO:0006355(regulation of transcription, DNA-dependent)|GO:0006367(transcription initiation from RNA polymerase II promoter)|GO:0006468(protein phosphorylation)|GO:0007049(cell cycle)|GO:0007067(mitosis)|GO:0009299(mRNA transcription)|GO:0016251(general RNA polymerase II transcription factor activity)|GO:0016301(kinase activity)|GO:0016740(transferase activity)|GO:0051301(cell division)
A_52_P1756341.973904 0.040809 A4gnt alpha-1,4-N-acetylglucosaminyltransferaseGO:0005575(cellular_compon nt)|GO:0006493(protein O-linked glycosylation)|GO:0008375(acetylglucosaminyltransferase activity)|GO:0009101(glycoprotein biosynthetic process)|GO:0016740(transferase activity)|GO:0016757(transferase activity, transferring glycosyl groups)|GO:0050680(negative regulation of epithelial cell proliferation)
A_55_P19976281.85163 0.005387
A_55_P20574591.750975 0.006405 Mall mal, T cell differentiation protein-likeGO:0000139(Golgi membrane)|GO:0003674(molecular_function)|GO:0005886(plasma membrane)|GO:0008150(biological_process)|GO:0016020(membrane)|GO:0016021(integral to membrane)|GO:0016023(cytoplasmic membrane-bounded vesicle)|GO:0030136(clathrin-coated vesicle)|GO:0045121(membrane raft)
A_55_P20597651.722417 0.013915 Foxf1 forkhead box F1GO:0000122(negative regulation of transcription from RNA polymerase II promoter)|GO:0001568(blood vessel development)|GO:0001570(vasculogenesis)|GO:0001701(in utero embryonic development)|GO:0001756(somitogenesis)|GO:0001763(morphogenesis of a branching structure)|GO:0002053(positive regulation of mesenchymal cell proliferation)|GO:0003197(endocardial cushion development)|GO:0003214(cardiac left ventricle morphogenesis)|GO:0003677(DNA binding)|GO:0003690(double-stranded DNA binding)|GO:0003700(sequence-specific DNA binding transcription factor activity)|GO:0003705(RNA polymerase II distal enhancer sequence-specific DNA binding transcription factor activity)|GO:0005634(nucleus)|GO:0005667(transcription factor complex)|GO:0006351(transcription, DNA-dependent)|GO:0006355(regulation of transcription, DNA-dependent)|GO:0007224(smoothened signaling pathway)|GO:0007368(determination of left/right symmetry)|GO:0007494(midgut development)|GO:0007498(mesoderm development)|GO:0007507(heart development)|GO:0008134(transc
A_55_P20217921.759163 0.049787 Dyrk1b dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1bGO:0000166(nucle tide binding)|GO:0003713(transcription coactivator activity)|GO:0004672(protein kinase activity)|GO:0004674(protein serine/threonine kinase activity)|GO:0004712(protein serine/threonine/tyrosine kinase activity)|GO:0004713(protein tyrosine kinase activity)|GO:0005524(ATP binding)|GO:0005634(nucleus)|GO:0006468(protein phosphorylation)|GO:0007520(myoblast fusion)|GO:0016301(kinase activity)|GO:0016310(phosphorylation)|GO:0016740(transferase activity)|GO:0016772(transferase activity, transferring phosphorus-containing groups)|GO:0043231(intracellular membrane-bounded organelle)|GO:0045893(positive regulation of transcription, DNA-dependent)
Supplementary Material (for online publication)
Click here to download Supplementary Material (for online publication): Table S2.xlsx
measurement IDFold ChangeLog2Ratio P-Value GENE_SYMBOLGENE_NAMEGO_ID Selection
A_65_P076268.307668 3.054444 0.010207 1
A_55_P21652343.722401 1.896234 0.001399 2300005B03RikRIKEN cDNA 2300005B03 geneGO: 3674(molecular_function)|GO:0005575(cellular_component)|GO:0008150(biological_process)1
A_55_P21768942.533281 1.341007 0.001827 1
A_55_P20022263.672292 1.876681 0.003 Dzip1 DAZ interacting protein 1GO:0005515(protein binding)|GO:0005622(intracellular)|GO:0005634(nucleus)|GO:0005737(cytoplasm)|GO:0007275(multicellular organismal development)|GO:0007283(spermatogenesis)|GO:0008270(zinc ion binding)|GO:0030154(cell differentiation)|GO:0036064(cilium basal body)|GO:0042384(cilium assembly)|GO:0046872(metal ion binding)1
A_55_P2145262.597939 1.377367 0.003074 Pex5l peroxisomal biogenesis factor 5-likeGO:0000268(peroxisome targeting sequence binding)|GO:0005052(peroxisome matrix targeting signal-1 binding)|GO:0005221(intracellular cyclic nucleotide activated cation channel activity)|GO:0005515(protein binding)|GO:0005737(cytoplasm)|GO:0005778(peroxisomal membrane)|GO:0005829(cytosol)|GO:0016020(membrane)|GO:0016558(protein import into peroxisome matrix)|GO:0016560(protein import into peroxisome matrix, docking)|GO:0017071(intracellular cyclic nucleotide activated cation channel complex)|GO:0017137(Rab GTPase binding)|GO:0030425(dendrite)|GO:0031267(small GTPase binding)|GO:0042391(regulation of membrane potential)|GO:0043949(regulation of cAMP-mediated signaling)|GO:0045055(regulated secretory pathway)|GO:0045185(maintenance of protein location)|GO:0048471(perinuclear region of cytoplasm)|GO:0051286(cell tip)|GO:0051461(positive regulation of corticotropin secretion)1
A_55_P21072391.778609 0.830749 0.001725 Ggn gametogenetinGO:0005515(protein binding)|GO:0005634(nucleus)|GO:0005635(nuclear envelope)|GO:0005730(nucleolus)|GO:0005737(cytoplasm)|GO:0006461(protein complex assembly)|GO:0007275(multicellular organismal development)|GO:0007283(spermatogenesis)|GO:0008104(protein localization)|GO:0016021(integral to membrane)|GO:0030154(cell differentiation)|GO:0031410(cytoplasmic vesicle)|GO:0046983(protein dimerization activity)|GO:0048471(perinuclear region of cytoplasm)1
A_55_P21730112.018861 1.013542 4.41E-04 Nfasc neurofascinGO:0002175(protein localization to paranode region of axon)|GO:0005622(intracellular)|GO:0005886(plasma membrane)|GO:0007155(cell adhesion)|GO:0007411(axon guidance)|GO:0007422(peripheral nervous system development)|GO:0016020(membrane)|GO:0016021(integral to membrane)|GO:0019226(transmission of nerve impulse)|GO:0030424(axon)|GO:0030913(paranodal junction assembly)|GO:0033010(paranodal junction)|GO:0033268(node of Ranvier)|GO:0033270(paranode region of axon)|GO:0042552(myelination)|GO:0043194(initial segment)|GO:0045162(clustering of voltage-gated sodium channels)|GO:0050808(synapse organization)|GO:0071205(protein localization to juxtaparanode region of axon)|GO:0072661(protein targeting to plasma membrane)|GO:0086080(protein binding involved in heterotypic cell-cell adhesion)1
A_52_P4875991.781307 0.832936 0.001765 Thnsl2 threonine synthase-like 2 (bacterial)GO:0004795(threonine synthase activity)|GO:0005575(cellular_component)|GO:0008152(metabolic process)|GO:0009071(serine family amino acid catabolic process)|GO:0009088(threonine biosynthetic process)|GO:0016311(dephosphorylation)|GO:0016829(lyase activity)|GO:0030170(pyridoxal phosphate binding)|GO:0046360(2-oxobutyrate biosynthetic process)|GO:0070905(serine binding)1
A_55_P20676291.755812 0.812139 0.001707 Ush1g Usher syndrome 1GGO:0005515(protein binding)|GO:0005737(cytoplasm)|GO:0005856(cytoskeleton)|GO:0005886(plasma membrane)|GO:0007605(sensory perception of sound)|GO:0015629(actin cytoskeleton)|GO:0016020(membrane)|GO:0042472(inner ear morphogenesis)|GO:0042803(protein homodimerization activity)|GO:0045494(photoreceptor cell maintenance)|GO:0050953(sensory perception of light stimulus)|GO:0050957(equilibrioception)|GO:0060113(inner ear receptor cell differentiation)1
A_55_P2140195.916453 0.938439 6.81E-04 1
A_55_P20258703.849947 1.944838 0.005937 Ccdc169 coiled-coil domain containing 169GO:0003674(molecular_function)|GO:0005575(cellular_component)|GO:0008150(biological_process)1
A_51_P3896642.134217 1.093707 8.76E-04 Scrt2 scratch homolog 2, zinc finger protein (Drosophila)GO:0003676(nucleic acid binding)|GO:0003677(DNA binding)|GO:0005622(intracellular)|GO:0005634(nucleus)|GO:0006351(transcription, DNA-dependent)|GO:0006355(regulation of transcription, DNA-dependent)|GO:0008150(biological_process)|GO:0008270(zinc ion binding)|GO:0046872(metal ion binding)1
A_55_P19573932.286358 1.193051 3.58E-04 1
A_55_P19983891.994891 0.99631 0.002202 1
A_55_P19888722.872486 1.5223 0.011269 Bcl11a B cell CLL/lymphoma 11A (zinc finger protein)GO:0003676(nucleic acid binding |GO:0003714(transcription corepressor activity)|GO:0005515(protein binding)|GO:0005622(intracellular)|GO:0005634(nucleus)|GO:0005737(cytoplasm)|GO:0006351(transcription, DNA-dependent)|GO:0006355(regulation of transcription, DNA-dependent)|GO:0008270(zinc ion binding)|GO:0010629(negative regulation of gene expression)|GO:0010976(positive regulation of neuron projection development)|GO:0010977(negative regulation of neuron projection development)|GO:0016604(nuclear body)|GO:0016925(protein sumoylation)|GO:0030183(B cell differentiation)|GO:0030217(T cell differentiation)|GO:0046872(metal ion binding)|GO:0046982(protein heterodimerization activity)|GO:0048671(negative regulation of collateral sprouting)|GO:0048672(positive regulation of collateral sprouting)|GO:0050773(regulation of dendrite development)|GO:2000171(negative regulation of dendrite development)1
A_52_P680283.24088 1.696386 0.021368 Ace angiotensin I converting enzyme (peptidyl-dipeptidase A) 1GO:0001822(kidney development)|GO:0002446(neutrophil mediated immunity)|GO:0003084(positive regulation of systemic arterial blood pressure)|GO:0003779(actin binding)|GO:0004175(endopeptidase activity)|GO:0004180(carboxypeptidase activity)|GO:0005576(extracellular region)|GO:0005615(extracellular space)|GO:0005768(endosome)|GO:0005886(plasma membrane)|GO:0006508(proteolysis)|GO:0006518(peptide metabolic process)|GO:0007283(spermatogenesis)|GO:0008144(drug binding)|GO:0008152(metabolic process)|GO:0008217(regulation of blood pressure)|GO:0008233(peptidase activity)|GO:0008237(metallopeptidase activity)|GO:0008241(peptidyl-dipeptidase activity)|GO:0008270(zinc ion binding)|GO:0009897(external side of plasma membrane)|GO:0014910(regulation of smooth muscle cell migration)|GO:0016020(membrane)|GO:0016021(integral to membrane)|GO:0016787(hydrolase activity)|GO:0019233(sensory perception of pain)|GO:0031100(organ regeneration)|GO:0031404(chloride ion binding)|GO:0031711(bradykinin receptor binding)|GO:0032496(respon1
A_55_P20869042.234258 1.159796 0.002157 1
A_55_P20325181.882102 0.912345 0.019196 Slc5a4a solute carrier family 5, member 4aGO:0005215(transporter activity)|GO:0006810(transport)|GO:0006811(ion transport)|GO:0006814(sodium ion transport)|GO:0008643(carbohydrate transport)|GO:0015078(hydrogen ion transmembrane transporter activity)|GO:0015293(symporter activity)|GO:0015992(proton transport)|GO:0016020(membrane)|GO:0016021(integral to membrane)|GO:0055085(transmembrane transport)1
A_55_P21787209.622099 3.266352 2.87E-06 1
A_55_P21047692.368195 1.243788 1.26E-04 Utf1 undifferentiated embryonic cell transcription factor 1GO:0003713(transcription coactivator activity)|GO:0005515(protein binding)|GO:0005634(nucleus)|GO:0006351(transcription, DNA-dependent)|GO:0006355(regulation of transcription, DNA-dependent)|GO:0045944(positive regulation of transcription from RNA polymerase II promoter)|GO:0071837(HMG box domain binding)1
A_51_P1025183.309079 1.72643 7.97E-05 Tmem225 transmembrane protein 225GO:0003674(molecular_function)|GO:0005575(cellular_component)|GO:0010923(negative regulation of phosphatase activity)|GO:0016020(membrane)|GO:0016021(integral to membrane)1
A_51_P2767153.36924 1.752423 1.05E-04 Olfr1350 olfactory receptor 1350GO:0004871(signal transducer activity)|GO:0004930(G-protein coupled receptor activity)|GO:0004984(olfactory receptor activity)|GO:0005886(plasma membrane)|GO:0007165(signal transduction)|GO:0007186(G-protein coupled receptor signaling pathway)|GO:0007608(sensory perception of smell)|GO:0016020(membrane)|GO:0016021(integral to membrane)|GO:0050896(response to stimulus)1
A_55_P21144372.162356 1.112604 0.003166 Pvalb parvalbuminGO:0005509(calcium ion binding)|GO:0005634(nucleus)|GO:0005737(cytoplasm)|GO:0030424(axon)|GO:0042803(protein homodimerization activity)|GO:0043234(protein complex)|GO:0046872(metal ion binding)|GO:0046982(protein heterodimerization activity)|GO:0051480(cytosolic calcium ion homeostasis)1
A_55_P19713731.905833 0.930422 0.001541 Nlrp12 NLR family, pyrin domain containing 12GO:0000166(nucleotide binding)|GO:0003674(molecular_function)|GO:0005524(ATP binding)|GO:0005634(nucleus)|GO:0005737(cytoplasm)|GO:0008588(release of cytoplasmic sequestered NF-kappaB)|GO:0009968(negative regulation of signal transduction)|GO:0031953(negative regulation of protein autophosphorylation)|GO:0032088(negative regulation of NF-kappaB transcription factor activity)|GO:0043122(regulation of I-kappaB kinase/NF-kappaB cascade)|GO:0043124(negative regulation of I-kappaB kinase/NF-kappaB cascade)|GO:0043281(regulation of cysteine-type endopeptidase activity involved in apoptotic process)|GO:0045345(positive regulation of MHC class I biosynthetic process)|GO:0045409(negative regulation of interleukin-6 biosynthetic process)|GO:0045751(negative regulation of Toll signaling pathway)|GO:0050710(negative regulation of cytokine secretion)|GO:0050711(negative regulation of interleukin-1 secretion)|GO:0050728(negative regulation of inflammatory response)1
A_55_P2109392.691839 1.88434 3.89E-04 Scn11a sodium channel, voltage-gated, type XI, alphaGO:0001518(voltage-gated sodium channel complex)|GO:0005216(ion channel activity)|GO:0005244(voltage-gated ion channel activity)|GO:0005248(voltage-gated sodium channel activity)|GO:0005272(sodium channel activity)|GO:0005515(protein binding)|GO:0005886(plasma membrane)|GO:0006810(transport)|GO:0006811(ion transport)|GO:0006814(sodium ion transport)|GO:0016020(membrane)|GO:0016021(integral to membrane)|GO:0030424(axon)|GO:0034220(ion transmembrane transport)|GO:0034765(regulation of ion transmembrane transport)|GO:0035725(sodium ion transmembrane transport)|GO:0044299(C-fiber)|GO:0055085(transmembrane transport)1
A_52_P1756341.973904 0.981052 0.040809 A4gnt alpha-1,4-N-acetylglucosaminyltransferaseGO:0005575(cellular_compon nt)|GO:0006493(protein O-linked glycosylation)|GO:0008375(acetylglucosaminyltransferase activity)|GO:0009101(glycoprotein biosynthetic process)|GO:0016740(transferase activity)|GO:0016757(transferase activity, transferring glycosyl groups)|GO:0050680(negative regulation of epithelial cell proliferation)1
A_55_P19976281.85163 0.888796 0.005387 1
A_55_P20574591.750975 0.808158 0.006405 Mall mal, T cell differentiation protein-likeGO:0000139(Golgi membrane)|GO:0003674(molecular_function)|GO:0005886(plasma membrane)|GO:0008150(biological_process)|GO:0016020(membrane)|GO:0016021(integral to membrane)|GO:0016023(cytoplasmic membrane-bounded vesicle)|GO:0030136(clathrin-coated vesicle)|GO:0045121(membrane raft)1
A_55_P20217921.759163 0.814889 0.049787 Dyrk1b dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1bGO:0000166(nucle tide binding)|GO:0003713(transcription coactivator activity)|GO:0004672(protein kinase activity)|GO:0004674(protein serine/threonine kinase activity)|GO:0004712(protein serine/threonine/tyrosine kinase activity)|GO:0004713(protein tyrosine kinase activity)|GO:0005524(ATP binding)|GO:0005634(nucleus)|GO:0006468(protein phosphorylation)|GO:0007520(myoblast fusion)|GO:0016301(kinase activity)|GO:0016310(phosphorylation)|GO:0016740(transferase activity)|GO:0016772(transferase activity, transferring phosphorus-containing groups)|GO:0043231(intracellular membrane-bounded organelle)|GO:0045893(positive regulation of transcription, DNA-dependent)1
A_55_P21350492.538173 1.34379 1.63E-04 1
A_55_P20523601.831663 0.873154 0.004644 Olfr1382 olfactory receptor 1382GO:0004871(signal transducer activity)|GO:0004930(G-protein coupled receptor activity)|GO:0004984(olfactory receptor activity)|GO:0007165(signal transduction)|GO:0007186(G-protein coupled receptor signaling pathway)|GO:0007608(sensory perception of smell)|GO:0016020(membrane)|GO:0016021(integral to membrane)1
A_51_P1103711.922133 0.942708 8.52E-04 Wwox WW domain-containing oxidoreductaseGO:0000166(nucleotide binding)|GO:0001105(RNA polymerase II transcription coactivator activity)|GO:0001649(osteoblast differentiation)|GO:0005515(protein binding)|GO:0005634(nucleus)|GO:0005737(cytoplasm)|GO:0005739(mitochondrion)|GO:0005794(Golgi apparatus)|GO:0005829(cytosol)|GO:0006915(apoptotic process)|GO:0006917(induction of apoptosis)|GO:0008152(metabolic process)|GO:0016055(Wnt receptor signaling pathway)|GO:0016491(oxidoreductase activity)|GO:0019899(enzyme binding)|GO:0030178(negative regulation of Wnt receptor signaling pathway)|GO:0043065(positive regulation of apoptotic process)|GO:0045944(positive regulation of transcription from RNA polymerase II promoter)|GO:0048705(skeletal system morphogenesis)|GO:0055114(oxidation-reduction process)|GO:0071560(cellular response to transforming growth factor beta stimulus)1
A_55_P21140691.719641 0.782107 0.030415 Hyls1 hydrolethalus syndrome 1GO:0003674(molecular_function)|GO:0005634(nucleus)|GO:0005737(cytoplasm)|GO:0005813(centrosome)|GO:0005886(plasma membrane)|GO:0008150(biological_process)1
A_51_P3625543.192259 1.674578 2.33E-04 Olfr1307 olfactory receptor 1307GO:0004871(signal transducer activity)|GO:0004930(G-protein coupled receptor activity)|GO:0004984(olfactory receptor activity)|GO:0005886(plasma membrane)|GO:0007165(signal transduction)|GO:0007186(G-protein coupled receptor signaling pathway)|GO:0007608(sensory perception of smell)|GO:0016020(membrane)|GO:0016021(integral to membrane)|GO:0050896(response to stimulus)1
A_55_P21279594.121563 2.043191 2.46E-04 Zfp36l3 zinc finger protein 36, C3H type-like 3GO:0000288(nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay)|GO:0000289(nuclear-transcribed mRNA poly(A) tail shortening)|GO:0003723(RNA binding)|GO:0005737(cytoplasm)|GO:0017091(AU-rich element binding)1
A_55_P21361847.046661 2.81694 1.14E-04 Sva seminal vesicle antigenGO:0005615(extracellular space)|GO:0071383(cellular response to steroid hormone stimulus)1
A_51_P3600041.81645 0.861122 5.47E-04 Ocstamp osteoclast stimulatory transmembrane proteinGO:0003674(molecula _functi n)|GO:0005575(cellular_component)|GO:0016020(membrane)|GO:0016021(integral to membrane)|GO:0030154(cell differentiation)|GO:0045672(positive regulation of osteoclast differentiation)|GO:0071356(cellular response to tumor necrosis factor)|GO:0071391(cellular response to estrogen stimulus)|GO:0072674(multinuclear osteoclast differentiation)|GO:0090290(positive regulation of osteoclast proliferation)1
A_55_P20248352.310471 1.208187 0.002324 Gm7104 REX1, RNA exonuclease 1 homolog pseudogene1
A_55_P1961414.71581 0.77889 0.013315 1
A_55_P20410602.056166 1.039957 0.001863 Rbp3 retinol binding protein 3, interstitialGO:0005576(ex racellular region)|GO:0005578(proteinaceous extracellular matrix)|GO:0006508(proteolysis)|GO:0006810(transport)|GO:0008236(serine-type peptidase activity)|GO:0016918(retinal binding)|GO:0019841(retinol binding)|GO:0033165(interphotoreceptor matrix)1
A_55_P19583792.041394 1.029554 2.32E-05 Slit1 slit homolog 1 (Drosophila)GO:0005102(receptor binding)|GO:0005509(calcium ion binding)|GO:0005576(extracellular region)|GO:0005615(extracellular space)|GO:0005737(cytoplasm)|GO:0007275(multicellular organismal development)|GO:0007399(nervous system development)|GO:0007409(axonogenesis)|GO:0007411(axon guidance)|GO:0008045(motor axon guidance)|GO:0021772(olfactory bulb development)|GO:0022028(tangential migration from the subventricular zone to the olfactory bulb)|GO:0022029(telencephalon cell migration)|GO:0030154(cell differentiation)|GO:0031290(retinal ganglion cell axon guidance)|GO:0033563(dorsal/ventral axon guidance)|GO:0040023(establishment of nucleus localization)|GO:0043395(heparan sulfate proteoglycan binding)|GO:0048495(Roundabout binding)|GO:0048812(neuron projection morphogenesis)|GO:0048843(negative regulation of axon extension involved in axon guidance)|GO:0048846(axon extension involved in axon guidance)|GO:0050919(negative chemotaxis)1
A_55_P2108271.455452 1.295988 8.34E-05 Ephb6 Eph receptor B6GO:0000166(nucleotide binding)|GO:0004672(protein kinase activity)|GO:0005003(ephrin receptor activity)|GO:0005524(ATP binding)|GO:0005576(extracellular region)|GO:0005886(plasma membrane)|GO:0005887(integral to plasma membrane)|GO:0006468(protein phosphorylation)|GO:0007169(transmembrane receptor protein tyrosine kinase signaling pathway)|GO:0016020(membrane)|GO:0016021(integral to membrane)|GO:0016772(transferase activity, transferring phosphorus-containing groups)|GO:0035898(parathyroid hormone secretion)|GO:0048013(ephrin receptor signaling pathway)|GO:0055074(calcium ion homeostasis)1
A_55_P20384842.81023 1.490688 0.00943 4933427D06RikRIKEN cDNA 4933427D06 geneGO:0003674(molecular_function)|GO:0005575(cellular_component)|GO:0008150(biological_process)1
A_55_P21839721.826778 0.869302 0.003106 Sh3bp1 SH3-domain binding protein 1GO:0005096(GTPase activator activity)|GO:0005622(intracellular)|GO:0005737(cytoplasm)|GO:0007165(signal transduction)|GO:0017124(SH3 domain binding)1
A_52_P6497241.961118 0.971677 0.003811 Smyd3 SET and MYND domain containing 3GO:0005575(cellular_component)|GO:0005634(nucleus)|GO:0005737(cytoplasm)|GO:0008168(methyltransferase activity)|GO:0008270(zinc ion binding)|GO:0016568(chromatin modification)|GO:0016740(transferase activity)|GO:0018024(histone-lysine N-methyltransferase activity)|GO:0032259(methylation)|GO:0034968(histone lysine methylation)|GO:0046872(metal ion binding)1
A_66_P1297123.379755 1.756919 1.33E-04 D030024E09RikRIKEN cDNA D030024E09 gene 1
GE_BrightCorner2.262746 1.178075 0.005464 1
A_55_P21357502.09655 1.068017 6.36E-04 1
A_51_P378336.002366 1.5861 0.00123 Coq3 coenzyme Q3 homolog, methyltransferase (yeast)GO:0004395(h xaprenyldihydroxybenzoate methyltransferase activity)|GO:0005739(mitochondrion)|GO:0006071(glycerol metabolic process)|GO:0006744(ubiquinone biosynthetic process)|GO:0008152(metabolic process)|GO:0008168(methyltransferase activity)|GO:0008425(2-polyprenyl-6-methoxy-1,4-benzoquinone methyltransferase activity)|GO:0008689(3-demethylubiquinone-9 3-O-methyltransferase activity)|GO:0016740(transferase activity)|GO:0032259(methylation)1
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measurement IDFold ChangeLog2Ratio P-Value GENE_SYMBOLGENE_NAMEGO_ID Selection
A_55_P21503982.153574 1.106733 7.91E-04 Cpne5 copine V GO:0003674(molecular_function)|GO:0008150(biological_process)|GO:0043005(neuron projection)|GO:0043025(neuronal cell body)1
A_52_P6099722.420619 1.275376 0.037332 Eln elastin GO:0001974(blood vessel remodeling)|GO:0005201(extracellular matrix structural constituent)|GO:0005515(protein binding)|GO:0005576(extracellular region)|GO:0005578(proteinaceous extracellular matrix)|GO:0005739(mitochondrion)|GO:0007519(skeletal muscle tissue development)|GO:0030023(extracellular matrix constituent conferring elasticity)|GO:0030198(extracellular matrix organization)|GO:0030833(regulation of actin filament polymerization)|GO:0043149(stress fiber assembly)|GO:0050840(extracellular matrix binding)|GO:0071953(elastic fiber)1
A_51_P1931732.57158 1.362655 2.35E-04 Slc25a25 solute carrier family 25 (mitochondrial carrier, phosphate carrier), member 25GO:0005509(calcium ion binding)|GO:0005739(mitochondrion)|GO:0005743(mitochondrial inner membrane)|GO:0006810(transport)|GO:0008150(biological_process)|GO:0016020(membrane)|GO:0016021(integral to membrane)|GO:0046872(metal ion binding)|GO:0055085(transmembrane transport)1
A_55_P2185185.992609 0.994659 5.60E-04 Tmem28 transmembrane protein 28GO:0003674(molecular_function)|GO:0005575(cellular_component)|GO:0008150(biological_process)|GO:0016020(membrane)|GO:0016021(integral to membrane)1
A_55_P19855912.217834 1.149152 0.034632 Cxx1a CAAX box 1AGO:0003674(molecular_function)|GO:0005575(cellular_component)|GO:0008150(biological_process)1
A_55_P19884811.922985 0.943348 0.002823 1
A_55_P22680221.996629 0.997566 0.008285 9330199G10RikRIKEN cDNA 9330199G10 gene 1
A_51_P3485921.804534 0.851626 0.035817 Slc38a7 solute carrier family 38, member 7GO:0005290(L-histidine transmembrane transporter activity)|GO:0005313(L-glutamate transmembrane transporter activity)|GO:0006810(transport)|GO:0006811(ion transport)|GO:0006814(sodium ion transport)|GO:0006865(amino acid transport)|GO:0015179(L-amino acid transmembrane transporter activity)|GO:0015180(L-alanine transmembrane transporter activity)|GO:0015182(L-asparagine transmembrane transporter activity)|GO:0015183(L-aspartate transmembrane transporter activity)|GO:0015186(L-glutamine transmembrane transporter activity)|GO:0015190(L-leucine transmembrane transporter activity)|GO:0015191(L-methionine transmembrane transporter activity)|GO:0015194(L-serine transmembrane transporter activity)|GO:0016020(membrane)|GO:0016021(integral to membrane)|GO:0030424(axon)|GO:0034220(ion transmembrane transport)|GO:0043025(neuronal cell body)1
A_55_P21350643.956673 1.984288 0.030769 H2-M2 histocompatibility 2, M region locus 2GO:0003674(molecular_function)|GO:0008150(biological_process)|GO:0009986(cell surface)1
A_55_P20687841.990991 0.993486 0.034442 Colq collagen-like tail subunit (single strand of homotrimer) of asymmetric acetylcholinesteraseGO:0005581(collagen)|GO:0008201(heparin binding)|GO:0030054(cell junction)|GO:0042135(neurotransmitter catabolic process)|GO:0045202(synapse)1
A_51_P4389674.210516 2.073997 0.012624 Gpnmb glycoprotein (transmembrane) nmbGO:0005178(integri  binding)|GO:0005887(integral to plasma membrane)|GO:0007155(cell adhesion)|GO:0008201(heparin binding)|GO:0016020(membrane)|GO:0016021(integral to membrane)|GO:0016023(cytoplasmic membrane-bounded vesicle)|GO:0031410(cytoplasmic vesicle)1
A_51_P1065911.706934 0.771407 0.026615 Celf3 CUGBP, Elav-like family member 3GO:0000166(nucleotide binding)|GO:0000381(regulation of alternative nuclear mRNA splicing, via spliceosome)|GO:0003676(nucleic acid binding)|GO:0003723(RNA binding)|GO:0005634(nucleus)|GO:0005737(cytoplasm)|GO:0006397(mRNA processing)|GO:0007283(spermatogenesis)|GO:0008380(RNA splicing)|GO:0030317(sperm motility)|GO:0048026(positive regulation of nuclear mRNA splicing, via spliceosome)1
A_66_P1071291.711738 0.775462 0.049891 3300005D01RikRIKEN cDNA 3300005D01 gene 1
A_51_P341918.972925 0.980336 2.97E-05 Tsc22d1 TSC22 domain family, member 1GO:0003700(sequence-specific DNA binding transcription factor activity)|GO:0005634(nucleus)|GO:0005737(cytoplasm)|GO:0006351(transcription, DNA-dependent)|GO:0006355(regulation of transcription, DNA-dependent)|GO:0008284(positive regulation of cell proliferation)|GO:0043065(positive regulation of apoptotic process)|GO:0043066(negative regulation of apoptotic process)1
A_55_P19640332.140484 1.097937 0.032632 Carm1 coactivator-associated arginine methyltransferase 1GO:0003420(regulation of g owth plate cartilage chondrocyte proliferation)|GO:0003713(transcription coactivator activity)|GO:0005515(protein binding)|GO:0005634(nucleus)|GO:0005737(cytoplasm)|GO:0005829(cytosol)|GO:0006351(transcription, DNA-dependent)|GO:0006355(regulation of transcription, DNA-dependent)|GO:0006479(protein methylation)|GO:0008168(methyltransferase activity)|GO:0008276(protein methyltransferase activity)|GO:0008284(positive regulation of cell proliferation)|GO:0008469(histone-arginine N-methyltransferase activity)|GO:0009405(pathogenesis)|GO:0016274(protein-arginine N-methyltransferase activity)|GO:0016568(chromatin modification)|GO:0016571(histone methylation)|GO:0016740(transferase activity)|GO:0019919(peptidyl-arginine methylation, to asymmetrical-dimethyl arginine)|GO:0030374(ligand-dependent nuclear receptor transcription coactivator activity)|GO:0030518(intracellular steroid hormone receptor signaling pathway)|GO:0030520(intracellular estrogen receptor signaling pathway)|GO:0032091(neg1
A_55_P21282201.96411 0.973876 0.00218 GO:0000079(regulation of cyclin-dependent protein kinase activity)|GO:0000166(nucleotide binding)|GO:0004672(protein kinase activity)|GO:0004674(protein serine/threonine kinase activity)|GO:0004693(cyclin-dependent protein kinase activity)|GO:0004702(receptor signaling protein serine/threonine kinase activity)|GO:0004713(protein tyrosine kinase activity)|GO:0005524(ATP binding)|GO:0005634(nucleus)|GO:0005675(holo TFIIH complex)|GO:0006355(regulation of transcription, DNA-dependent)|GO:0006367(transcription initiation from RNA polymerase II promoter)|GO:0006468(protein phosphorylation)|GO:0007049(cell cycle)|GO:0007067(mitosis)|GO:0009299(mRNA transcription)|GO:0016251(general RNA polymerase II transcription factor activity)|GO:0016301(kinase activity)|GO:0016740(transferase activity)|GO:0051301(cell division)1
A_55_P20597651.722417 0.784435 0.013915 Foxf1 forkhead box F1GO:0000122(negative regulation of transcription from RNA polymerase II promoter)|GO:0001568(blood vessel development)|GO:0001570(vasculogenesis)|GO:0001701(in utero embryonic development)|GO:0001756(somitogenesis)|GO:0001763(morphogenesis of a branching structure)|GO:0002053(positive regulation of mesenchymal cell proliferation)|GO:0003197(endocardial cushion development)|GO:0003214(cardiac left ventricle morphogenesis)|GO:0003677(DNA binding)|GO:0003690(double-stranded DNA binding)|GO:0003700(sequence-specific DNA binding transcription factor activity)|GO:0003705(RNA polymerase II distal enhancer sequence-specific DNA binding transcription factor activity)|GO:0005634(nucleus)|GO:0005667(transcription factor complex)|GO:0006351(transcription, DNA-dependent)|GO:0006355(regulation of transcription, DNA-dependent)|GO:0007224(smoothened signaling pathway)|GO:0007368(determination of left/right symmetry)|GO:0007494(midgut development)|GO:0007498(mesoderm development)|GO:0007507(heart development)|GO:0008134(transc1
A_55_P21820061.953938 0.966385 0.001928 Cacng6 calcium channel, voltage-dependent, gamma subunit 6GO:0005216(ion channel activity)|GO:0005244(voltage-gated ion channel activity)|GO:0005262(calcium channel activity)|GO:0006810(transport)|GO:0006811(ion transport)|GO:0006816(calcium ion transport)|GO:0016020(membrane)|GO:0016021(integral to membrane)|GO:0034765(regulation of ion transmembrane transport)|GO:0070588(calcium ion transmembrane transport)1
A_55_P2052361.059473 1.613283 4.04E-04 Olfr1382 olfactory receptor 1382GO:0004871(signal transducer activity)|GO:0004930(G-protein coupled receptor activity)|GO:0004984(olfactory receptor activity)|GO:0007165(signal transduction)|GO:0007186(G-protein coupled receptor signaling pathway)|GO:0007608(sensory perception of smell)|GO:0016020(membrane)|GO:0016021(integral to membrane)1
A_55_P21828351.961906 0.972256 6.51E-05 Chrnb4 cholinergic receptor, nicotinic, beta polypeptide 4GO:0001508(regulation of action potential)|GO:0004889(acetylcholine-activated cation-selective channel activity)|GO:0005216(ion channel activity)|GO:0005230(extracellular ligand-gated ion channel activity)|GO:0005886(plasma membrane)|GO:0005892(acetylcholine-gated channel complex)|GO:0006810(transport)|GO:0006811(ion transport)|GO:0006939(smooth muscle contraction)|GO:0006940(regulation of smooth muscle contraction)|GO:0007165(signal transduction)|GO:0007626(locomotory behavior)|GO:0015464(acetylcholine receptor activity)|GO:0016020(membrane)|GO:0016021(integral to membrane)|GO:0030054(cell junction)|GO:0035094(response to nicotine)|GO:0035095(behavioral response to nicotine)|GO:0042166(acetylcholine binding)|GO:0042391(regulation of membrane potential)|GO:0043005(neuron projection)|GO:0045202(synapse)|GO:0045211(postsynaptic membrane)|GO:0060084(synaptic transmission involved in micturition)1
A_51_P3478623.236079 1.694247 0.027118 Actn1 actinin, alpha 1GO:0001725(stress fiber)|GO:0003779(actin binding)|GO:0005178(integrin binding)|GO:0005509(calcium ion binding)|GO:0005515(protein binding)|GO:0005634(nucleus)|GO:0005737(cytoplasm)|GO:0005856(cytoskeleton)|GO:0005886(plasma membrane)|GO:0005916(fascia adherens)|GO:0005925(focal adhesion)|GO:0016020(membrane)|GO:0017166(vinculin binding)|GO:0019904(protein domain specific binding)|GO:0030018(Z disc)|GO:0030141(secretory granule)|GO:0030863(cortical cytoskeleton)|GO:0030864(cortical actin cytoskeleton)|GO:0030865(cortical cytoskeleton organization)|GO:0032127(dense core granule membrane)|GO:0042803(protein homodimerization activity)|GO:0042995(cell projection)|GO:0043197(dendritic spine)|GO:0044325(ion channel binding)|GO:0046872(metal ion binding)|GO:0048041(focal adhesion assembly)|GO:0051015(actin filament binding)|GO:0051017(actin filament bundle assembly)|GO:0051271(negative regulation of cellular component movement)|GO:0070062(extracellular vesicular exosome)1
A_55_P20197641.918571 0.940032 0.016742 1
A_51_P210814.812894 0.858295 0.018748 Nudt18 nudix (nucleoside diphosphate linked moiety X)-type motif 18GO:0000287(magnesium ion binding)|GO:0005575(cellular_component)|GO:0016787(hydrolase activity)|GO:0046057(dADP catabolic process)|GO:0046067(dGDP catabolic process)|GO:0046712(GDP catabolic process)|GO:0046872(metal ion binding)1
A_55_P19781863.358355 1.747755 2.41E-04 BC089597 cDNA sequence BC089597GO:0003674(molecular_function)|GO:0005575(cellular_component)|GO:0008150(biological_process)1
A_55_P23508032.895082 1.533604 7.14E-04 DXErtd223eDNA segment, Chr X, ERATO Doi 223, expressed1
A_55_P20384892.601975 1.379607 0.011546 1
A_55_P2185148.875482 0.907261 0.003458 Mettl7a3 methyltransferase like 7A3GO:0003674(molecular_function)|GO:0005575(cellular_component)|GO:0008150(biological_process)1
A_66_P1372853.208132 1.681733 5.78E-04 A730045E13RikRIKEN cDNA A730045E13 geneGO:0 3674(molecular_function)|GO:0005575(cellular_component)|GO:0008150(biological_process)1
A_55_P19724412.403847 1.265345 0.001814 1
A_55_P21499271.744885 0.803132 3.86E-04 Gm5101 predicted gene 5101GO:00 3674(molecular_function)|GO:0005575(cellular_component)|GO:0008150(biological_process)1
A_55_P21093271.765495 0.820072 0.035157 Ache acetylcholinesteraseGO:0001919(regulation of receptor recycling)|GO:0003990(acetylcholinesterase activity)|GO:0004091(carboxylesterase activity)|GO:0004104(cholinesterase activity)|GO:0005518(collagen binding)|GO:0005576(extracellular region)|GO:0005605(basal lamina)|GO:0005615(extracellular space)|GO:0005635(nuclear envelope)|GO:0005737(cytoplasm)|GO:0005788(endoplasmic reticulum lumen)|GO:0005791(rough endoplasmic reticulum)|GO:0005794(Golgi apparatus)|GO:0005886(plasma membrane)|GO:0006581(acetylcholine catabolic process)|GO:0007155(cell adhesion)|GO:0007271(synaptic transmission, cholinergic)|GO:0007416(synapse assembly)|GO:0008291(acetylcholine metabolic process)|GO:0009986(cell surface)|GO:0016020(membrane)|GO:0016787(hydrolase activity)|GO:0017171(serine hydrolase activity)|GO:0019695(choline metabolic process)|GO:0030054(cell junction)|GO:0030424(axon)|GO:0030425(dendrite)|GO:0031225(anchored to membrane)|GO:0031594(neuromuscular junction)|GO:0031623(receptor internalization)|GO:0033265(choline binding)|GO:0042135(neurot1
A_52_P4833362.915783 1.543883 0.010482 Ms4a1 membrane-spanning 4-domains, subfamily A, member 1GO:0005154(epidermal growth factor receptor binding)|GO:0005730(nucleolus)|GO:0009897(external side of plasma membrane)|GO:0016020(membrane)|GO:0016021(integral to membrane)|GO:0042113(B cell activation)1
A_55_P21093262.148441 1.10329 0.027633 Ache acetylcholinesteraseGO:0001919(regulation of receptor recycling)|GO:0003990(acetylcholinesterase activity)|GO:0004091(carboxylesterase activity)|GO:0004104(cholinesterase activity)|GO:0005518(collagen binding)|GO:0005576(extracellular region)|GO:0005605(basal lamina)|GO:0005615(extracellular space)|GO:0005635(nuclear envelope)|GO:0005737(cytoplasm)|GO:0005788(endoplasmic reticulum lumen)|GO:0005791(rough endoplasmic reticulum)|GO:0005794(Golgi apparatus)|GO:0005886(plasma membrane)|GO:0006581(acetylcholine catabolic process)|GO:0007155(cell adhesion)|GO:0007271(synaptic transmission, cholinergic)|GO:0007416(synapse assembly)|GO:0008291(acetylcholine metabolic process)|GO:0009986(cell surface)|GO:0016020(membrane)|GO:0016787(hydrolase activity)|GO:0017171(serine hydrolase activity)|GO:0019695(choline metabolic process)|GO:0030054(cell junction)|GO:0030424(axon)|GO:0030425(dendrite)|GO:0031225(anchored to membrane)|GO:0031594(neuromuscular junction)|GO:0031623(receptor internalization)|GO:0033265(choline binding)|GO:0042135(neurot1
A_55_P20237831.897563 0.924148 0.007127 Leng8 leukocyte receptor cluster (LRC) member 8GO:0005575(cellular_co ponent)|GO:0008150(biological_process)1
A_55_P20106721.736069 0.795825 1.11E-04 Kif17 kinesin family member 17GO:0000166(nucleotide binding)|GO:0003777(microtubule motor activity)|GO:0005515(protein binding)|GO:0005524(ATP binding)|GO:0005737(cytoplasm)|GO:0005856(cytoskeleton)|GO:0005871(kinesin complex)|GO:0005874(microtubule)|GO:0005875(microtubule associated complex)|GO:0006810(transport)|GO:0007017(microtubule-based process)|GO:0007018(microtubule-based movement)|GO:0008152(metabolic process)|GO:0015031(protein transport)|GO:0016192(vesicle-mediated transport)|GO:0031503(protein complex localization)1
A_55_P20671512.057469 1.040871 0.002844 1
A_55_P2087280.016144 1.011599 1.01E-04 1
A_55_P19598431.733411 0.793614 0.014242 1
A_66_P1102511.839291 0.87915 1.64E-04 Tmem91 transmembrane protein 91GO:0003674(molecular_function)|GO:0005575(cellular_component)|GO:0008150(biological_process)|GO:0009607(response to biotic stimulus)|GO:0016020(membrane)|GO:0016021(integral to membrane)1
A_55_P21357251.748813 0.806376 0.017496 C8g complement component 8, gamma polypeptideGO:0001848(comple ent binding)|GO:0005576(extracellular region)|GO:0005579(membrane attack complex)|GO:0005615(extracellular space)|GO:0006957(complement activation, alternative pathway)|GO:0006958(complement activation, classical pathway)|GO:0019835(cytolysis)|GO:0019841(retinol binding)|GO:0032403(protein complex binding)|GO:0036094(small molecule binding)|GO:0045087(innate immune response)1
A_55_P21706992.070768 1.050166 0.002247 1
A_55_P19569532.799554 1.485197 0.001862 1
A_55_P24123291.765981 0.82047 0.00345 4930581F22RikRIKEN cDNA 4930581F22 geneGO:0 03674(molecular_function)|GO:0005575(cellular_component)|GO:0008150(biological_process)1
A_55_P2136145.862149 0.896969 4.35E-04 Cnn3 calponin 3, acidicGO:0003779(actin binding)|GO:0005515(protein binding)|GO:0005516(calmodulin binding)|GO:0008017(microtubule binding)|GO:0014069(postsynaptic density)|GO:0030425(dendrite)|GO:0031032(actomyosin structure organization)|GO:0032780(negative regulation of ATPase activity)|GO:0043025(neuronal cell body)|GO:0043197(dendritic spine)1
A_55_P20977732.402795 1.264713 0.012046 Msh4 mutS homolog 4 (E. coli)GO:0000166(nucleotide binding)|GO:0000793(condensed chromosome)|GO:0000794(condensed nuclear chromosome)|GO:0000795(synaptonemal complex)|GO:0001541(ovarian follicle development)|GO:0003677(DNA binding)|GO:0005524(ATP binding)|GO:0005634(nucleus)|GO:0006298(mismatch repair)|GO:0007126(meiosis)|GO:0007129(synapsis)|GO:0007131(reciprocal meiotic recombination)|GO:0007283(spermatogenesis)|GO:0007292(female gamete generation)|GO:0008094(DNA-dependent ATPase activity)|GO:0030983(mismatched DNA binding)|GO:0045143(homologous chromosome segregation)|GO:0051026(chiasma assembly)1
A_55_P20080162.384703 1.253809 0.035638 Armc3 armadillo repeat containing 3GO:0003674(molecular_function)|GO:0005575(cellular_component)|GO:0008150(biological_process)1
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Casein, 30 Mesh 228 912
DL-Methionine 2 0
Maltodextrin 10 170 680
Corn Starch 0 0
Sucrose 175 700
Soybean Oil 25 225
Conconut Oil 333.5 3001.5
Mineral Mix 40 0
Sodium Bicarbonate 10.5 0
Potassium Citrate 4 0
Vitamin Mix 10 40
Choline Bitartrate 2 0
FD&C Red Dye 0.1 0
Total 1000.1 5558.5
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 Thin layer chromatography 
 
For the analysis of lipid, frozen kidney tissue samples (4 % wt/vol) were homogenized 
with a tight fitting glass-teflon homogenizer at full speed in 250 mM sucrose, 10 mM 
Tris/HCl pH 7.4 (supplemented with Complete Mini protease inhibitors from Roche). 1 
mg of homogenate (BCA protein determination kit from Interchim, Montlucon, France) 
was extracted as determined as described in [1]. The extracted lipids were analyzed 
for phospholipid and cholesterol content by thin-layer chromatography as described in 
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